Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
good morning brigg... i posted the share structyure from pink sheets yesterday... is that info not correct
Good Morning FRMC Board!!!
yea thats what i was thinking too
Overture Acquisition Corp. Adjourns Extraordinary General Meeting of Shareholders and Special Meeting of Warrantholders
Buzz up! 0 Print..Companies:Overture Acquisition Corp.Related Quotes
Symbol Price Change
NLX 9.48 -0.10
{"s" : "nlx","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Overture Acquisition Corp. On Wednesday January 27, 2010, 12:37 pm
GRAND CAYMAN, Cayman Islands--(BUSINESS WIRE)--Overture Acquisition Corp. (“Overture”) (NYSE Amex: NLX) today announced that it convened and adjourned the extraordinary general meeting of shareholders and the special meeting of warrantholders to 10:00 a.m. and 10:30 a.m. Eastern Time, respectively, on Friday, January 29, 2010 at the same location in order to give Overture shareholders and warrantholders additional time to consider and vote on the proposals to be considered at that Extraordinary General Meeting and the Special Meeting of Warrantholders.
The record date for shareholders entitled to vote at the extraordinary general meeting of shareholders and for warrantholders entitled to vote at the special meeting of warrantholders remains the close of business on January 7, 2010. The full meeting agendas are detailed in the definitive proxy statement/prospectus, which has been mailed to all Overture shareholders and warrantholders of record as of the close of business on January 7, 2010. As more fully described in Overture's definitive proxy statement/prospectus, shareholders and warrantholders may revoke their proxy and change their vote at any time before the applicable shareholder and warrantholder meetings. Investors and security holders are advised to read the definitive proxy statement/prospectus because it contains important information.
Additional information regarding Overture, the proposed amalgamation and the related transactions is available in the definitive proxy statement/prospectus and Overture’s Current Reports on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on December 10, 2009, December 24, 2009, December 30, 2009, January 11, 2010, and January 26, 2010 (the “Current Reports”), copies of which, together with other reports filed by the Company, may be obtained without charge, at the SEC’s website at http://www.sec.gov.
Not a Proxy Statement/Prospectus
This press release is not a proxy statement/prospectus or a solicitation of proxies from the holders of Overture’s securities. Any solicitation of proxies will be made only pursuant to the definitive proxy statement/prospectus mailed to all Overture shareholders and warrantholders who hold such securities as of the record date. Interested investors and security holders are urged to read the definitive proxy statement/prospectus, appendices thereto and the Current Reports because they contain important information about Overture, Jefferson National Financial Corp., Jefferson National Life Insurance Company, and the proposals to be presented at the Extraordinary General Meeting of Shareholders and the Special Meeting of Warrantholders, as the case may be.
About Overture Acquisition Corp.
Overture Acquisition Corp. is a special purpose acquisition corporation incorporated in the Cayman Islands on September 25, 2007 as an exempted company. It is a company formed for the purpose of effecting a merger, share capital exchange, asset acquisition, share purchase, reorganization or similar business combination, with one or more businesses.
About Jefferson National Life Insurance Company
Jefferson National Life Insurance Company is a Texas insurance company and a wholly owned subsidiary of Jefferson National Financial Corp. JNL was founded in 1937, is licensed in 49 states and run by current management team since 2003. JNL currently offers annuity products through multiple distribution channels.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Overture, JNF, JNL and Overture’s business after completion of the proposed transactions. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of the management of Overture, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the Forward-Looking Statements: (i) Overture’s ability to complete its proposed business combination within the specified time limits; (ii) officers and directors allocating their time to other businesses or potentially having conflicts of interest with Overture’s business or in approving the Transaction; (iii) success in retaining or recruiting, or changes required in, Overture’s officers, key employees or directors following the Transaction; (iv) delisting of Overture’s securities from the NYSE Amex following the Transaction; (v) the potential liquidity and trading of Overture’s public securities; (vi) Overture’s revenues and operating performance; (vii) changes in overall economic conditions; (viii) anticipated business development activities of Overture following the Transaction; (ix) changing interpretations of generally accepted accounting principles, (x) continued compliance with government regulations, (xi) changing legislation or regulatory environments (xii) risks and costs associated with regulation of corporate governance and disclosure standards (including pursuant to Section 404 of the Sarbanes-Oxley Act of 2002); and (xiii) other relevant risks detailed in Overture’s filings with the SEC and those factors listed in the Definitive Proxy Statement/Prospectus under “Risk Factors.” The information set forth herein should be read in light of such risks. None of Overture, JNF, or JNL assumes any obligation to update the information contained in this release.
Additional Information and Where to Find It
This press release is being made pursuant to and in compliance with Rules 145, 165 and 425 of the Securities Act of 1933, as amended, and does not constitute an offer of any securities for sale or a solicitation of an offer to buy any securities. Overture, JNF, JNL and their respective directors and officers may be deemed to be participants in the solicitation of proxies for the special meetings of Overture’s shareholders and warrantholders to be held to approve the proposed transactions described herein. The underwriters of Overture’s initial public offering may provide assistance to Overture, JNF, JNL and their respective directors and executive officers, and may be deemed to be participants in the solicitation of proxies. A substantial portion of the underwriters’ fees relating to Overture’s initial public offering were deferred pending stockholder approval of Overture’s initial business combination, and shareholders are advised that the underwriters have a financial interest in the successful outcome of the proxy solicitation. In connection with the proposed Transaction (and related transactions) and amendment to the warrant agreement, Overture has filed with the SEC a definitive proxy statement/prospectus. Overture’s shareholders and warrantholders are advised to read the definitive proxy statement/prospectus and other documents filed with the SEC in connection with the solicitation of proxies for the Extraordinary General Meeting of Shareholders and the Special Meeting or Warrantholders because these documents contain important information. The definitive proxy statement/prospectus will be mailed to Overture’s shareholders and warrantholders as of January 7, 2010. Overture’s shareholders and warrantholders will also be able to obtain a copy of the definitive proxy statement/prospectus, without charge, by directing a request to: Overture Acquisition Corp., 1133 Avenue of the Americas, Suite 3100, New York, New York 10036-6710, Attn: Mark Blazer, President. The definitive proxy statement/prospectus can also be obtained, without charge, at the SEC’s website at http://www.sec.gov.
Contact:
Overture Acquisition Corp.Marc J. Blazer, President and Treasurer, 646-736-1376
Caterpillar forecast disappoints; shares fall
Buzz up! 0 Print..Companies:Caterpillar Inc..
Reuters - A worker drives a Caterpillar tractor near a construction site in Gilbert, Arizona October 20, 2009. REUTERS/Joshua Lott ...
Related Quotes
Symbol Price Change
CAT 52.05 -3.80
{"s" : "cat","k" : "c10,l10,p20,t10","o" : "","j" : ""} On Wednesday January 27, 2010, 12:29 pm
By James B. Kelleher
CHICAGO (Reuters) - Caterpillar Inc (NYSE:CAT - News), the world's largest maker of construction and mining equipment, offered an unexpectedly guarded view of the coming year on Wednesday, sending its stock down more than 8 percent and pulling the broad market down along with it.
The cautious outlook from the bellwether company came as Caterpillar posted stronger-than-expected quarterly earnings and said it was seeing encouraging signs that economies around the world were rebounding from a recession that hammered its sales over the past year.
But the company, a component of the Dow Jones industrial average, also forecast 2010 earnings below the average Wall Street estimate. It said it now expects to report a profit of $2.50 a share on sales of $35.6 billion to $40.5 billion as the rebound from the recent global downturn favors some of its markets and products over others.
That was below the $2.71 a share profit analysts expected, according to Thomson Reuters I/B/E/S -- and well below the $3 a share "whisper number" that Eli Lustgarten, an analyst at Longbow Securities, said was circulating among some investors ahead of the forecast.
"So they're offering a little more cautious outlook on profitability than some of the more optimistic analysts were hoping for," Lustgarten said.
Caterpillar said it expects the world economy to grow more than 3 percent in 2010, led by developing economies like China, which it said would grow more than 10 percent.
It warned that the United States, the world's largest economy, would grow just 3.5 percent, well below levels seen in past recoveries.
Caterpillar said a continued decline in nonresidential building construction, and delays in passing a highway bill, would "likely will cause highway contractors to remain cautious about purchasing equipment."
That's bad news for Caterpillar and other makers of construction equipment, which are already grappling with a precipitous drop in sales to residential builders because of the collapse of real estate prices in North America and Europe.
The disappointing forecast came as Caterpillar reported a fourth-quarter net profit of $232 million, or 36 cents a share, down from $661 million, or $1.08 a share, a year earlier.
Sales fell 39 percent to $7.9 billion.
Stripping out costs associated with the company's restructuring, which involved the elimination of nearly 25,000 jobs worldwide, Caterpillar said it earned 41 cents a share.
On that basis, analysts, on average, expected the Peoria, Ilinois-based company to report a profit of 28 cents a share, on sales of $8.11 billion, according to Thomson Reuters I/B/E/S.
Caterpillar, which has described the downturn in its business in 2009 as the worst since the Great Depression, said it was seeing encouraging signs of a rebound in interest for many of its products.
"We have seen a marked increase in demand for mining equipment -- a result of continued strong commodity prices and growing confidence in economic recovery," Jim Owens, the company's chairman and chief executive, said in a statement.
Owens said the company had also seen an increase in sales of aftermarket service parts, which he said "is usually an early indicator of growing demand for machines and engines."
But the company said that many of the factors that helped support earnings in 2009 would not be there in 2010, including
low income taxes and accounting benefits related to inventory
reductions.
In addition, it warned that sales of its higher margin products, including turbines and large reciprocating engines, would fall in 2010. It said the "impact of improving demand for mining equipment is positive, but not enough to offset the significant negative factors."
In morning trading on the New York Stock Exchange, Caterpillar shares were down 8.4 percent at $51.16.
(Reporting by James B. Kelleher; editing by John Wallace, Dave Zimmerman)
hey whats happenin gmoney... looking for a breakout here... last trade .38 60K vol
FRMC 48.6K vol 3x the 10 day avg here... Looking to move north
48.6K vol 3x the 10 day avg here... Looking to move north
Following Merger of Generali and Volksfuersorge Insurance Companies, A.M. Best Withdraws Ratings of the Transferred Companies
Buzz up! 0 Print..Press Release Source: A.M. Best Co. On Wednesday January 27, 2010, 12:10 pm
LONDON--(BUSINESS WIRE)--A.M. Best Co. has withdrawn the financial strength rating (FSR) of A+ (Superior) and issuer credit rating (ICR) of “aa-” and assigned an NR -5 (Not Formally Followed) to the FSR and an “nr” to the ICR of Generali Versicherung Aktiengesellschaft and Generali Lebensversicherung Aktiengesellschaft, following their merger into Volksfuersorge Deutsche Sachversicherung Aktiengesellschaft and Volksfuersorge Deutsche Lebenversicherung Aktiengesellschaft, respectively.
Volksfuersorge Deutsche Sachversicherung Aktiengesellschaft was renamed Generali Versicherung Aktiengesellschaft, and Volksfuersorge Deutsche Lebensversicherung Aktiengesellschaft was renamed Generali Lebensversicherung Aktiengesellschaft. These renamed entities currently have an FSR of A+ (Superior) and an ICR of “aa-”. All companies are domiciled in Germany.
For Best’s Credit Ratings, an overview of the rating process and rating methodologies, please visit www.ambest.com/ratings.
The principal methodologies used in determining these ratings, including any additional methodologies and factors that may have been considered, can be found at www.ambest.com/ratings/methodology.
Founded in 1899, A.M. Best Company is a global full-service credit rating organization dedicated to serving the financial and health care service industries, including insurance companies, banks, hospitals and health care system providers. For more information, visit www.ambest.com.
Contact:
A.M. Best Co.AnalystsCharlotte Vigier, +(44) 20 7626 6264 +(44) 20 7626 6264charlotte.vigier@ambest.comorVasilis Katsipis, +(44) 20 7626 6264 +(44) 20 7626 6264vasilis.katsipis@ambest.comorPublic RelationsJim Peavy, +(1) 908-439-2200 +(1) 908-439-2200, ext. 5644james.peavy@ambest.comorRachelle Morrow, +(1) 908-439-2200 +(1) 908-439-2200, ext. 5378rachelle.morrow@ambest.com
Research and Markets: The 'Financial Analysis - Manitowoc Company' Presents a Complete Ownership Pattern of the Company Which Is Very Critical Information in M&A Activity
.Press Release Source: Research and Markets On Wednesday January 27, 2010, 12:00 pm
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8559a4/financial_analysis) has announced the addition of the "Financial Analysis - Manitowoc Company" company profile to their offering.
Business scenario in today's context - niche opportunities, limited time periods, ever increasing risk and the need for precise decision making, which if not done correctly would run the costs in million even before brakes are exercised. That is the speed of business in today's high octane economies which are constantly metamorphosing into global empires of influence.
Even the best decision makers have made mistakes which have wiped out entire reserves built over a period of hard work by the company's stakeholders including the employees. The responsibility imposed on the shoulders of senior management is immense and does not leave much room for mistakes to be absorbed by the interest holders in the company.
In this scenario, the management needs a good, strong and logic driven decision making tool which and can serve as easily referable, is common in language, can be applied globally with standard parameters as also is accepted by various independent assessors.
A tool as useful as this which is numerically driven and with accepted logic is this Financial Analysis.
This Financial Analysis is a compact, focused report which helps management's critical decision making by lending itself to analyzing a company's profitability, solvency as well as financial stability. These facts from this Financial Analysis helps the management to make different decisions on segregating priority businesses, present funding requirements, mergers and acquisition activities, etc.
This Financial Analysis brings to the management a complete profile of the company which is under consideration and also provides an insight on the business segments in which the company operates as well as its subsidiaries and some of the key executives of that company.
The Financial Analysis report further presents a complete ownership pattern of the company which is very critical information in M&A activity in order for the management to plan the acquisition accordingly. The ownership pattern analysis is as declared at the last AGM of the organization unless fuelled by some exceptional activity mid-year.
This Financial Analysis report combines a complete SWOT analysis of the company thereby increasing the strategic management analysis presented in the report. The report documents a complete board of the latest financial information of the company including stock prices over a period, earnings per share, income statements, balance sheets, EPS growth Qtr. on Qtr. and Yr. over Yr.
The report further presents the complete array of financial ratios of the company which points to the basic health of its activities and even goes a step further to present the efficiency of the company's management. Some of the ratios as Price, Profitability, Liquidity, give a very accurate picture of the financial health of the company and are explained in detail in this Financial Analysis.
Another key parameter which the report analyses is the position of the vis-?-vis its competition in the market. This helps the decision maker decide clearly what strategic position the firm enjoys in the market currently and whether there is opportunity for the investor to take it further in the future or whether the firm's competitors are too strong which means the firm will need more financial effort to move forward. This analysis enables the investor to decide the future course of action as well as make a guarded offer in lieu of the risks that the investor is about to undertake.
This Financial Analysis report also provides a future perspective of the company and its growth prospects.
This Financial Analysis is a complete power researched capsule of the real strengths of a company and provides the numerical decision making tool for the investor which is objective as well as globally accepted. The report is a critical interface which helps investors sift through opportunities and pick the correct one as per their risk appetites and financial acumen.
In the ever increasing haze of globalization wherein it is imperative for organizations to expand their global footprint either by investing or by mergers & acquisitions, This Financial Analysis helps them steer the right business direction to islands of profit mining and greater returns on their invested capital.
The report will be updated at the time of delivery.
Key Topics Covered:
•Executive Summary
•Introduction to the Company
•Analyzing the Ownership Pattern in the Company
•SWOT Framework Analysis
•Financial Analysis
•Analyzing the Key Ratios
•Undertaking a Profitability Analysis
•Competitor Group Analysis
•Future Perspective of the Company
•Appendix
•Glossary of Terms
For more information visit http://www.researchandmarkets.com/research/8559a4/financial_analysis
Contact:
Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comU.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481
Oil prices inch up as demand remains weak
Crude prices slightly higher as demand remains weaker than at worst of the recession
Buzz up! 0 Print..Companies:Ipath SP Gsci Crude Oil Ttl Ret Idx EtnUnited States Natural GasUnited States Oil.
AP - Reed Richards fills a home heating oil tank in Valencia, Pa., Monday Jan. 25, 2010. Crude, natural gas ...
Related Quotes
Symbol Price Change
OIL 24.14 +0.10
UNG 9.46 -0.38
USO 36.64 +0.14
{"s" : "oil,ung,uso","k" : "c10,l10,p20,t10","o" : "","j" : ""} By Mark Williams, AP Energy Writer , On Wednesday January 27, 2010, 11:51 am
Oil prices were slightly higher Wednesday after a government report showed demand for crude products dropped even further from the weak levels of a year ago when the recession's grip on the economy was strongest.
Benchmark crude for March delivery rose 12 cents to $74.84 a barrel on the New York Mercantile Exchange. The contract dropped 55 cents to settle at $74.71 on Tuesday.
The Energy Information Administration said Wednesday that demand for gasoline fell 0.8 percent over the four weeks ended Friday compared with a year ago and that demand for distillates used for heating oil and diesel fuel is off 8.1 percent.
Even though the economy has pulled out of recession, unemployment remains stubbornly high at levels last seen more than a generation ago. Industrial production is still weak. That has undercut demand for of all kinds of energy -- from natural gas to run factories and power plants to gasoline for weekend trips and vacations.
Analyst and trader Stephen Schork said it's hard to imagine demand being lower than a year ago. "That is when we were in the abyss," he said.
Schork wondered whether the move to more fuel-efficient vehicles could also be part of the reason for lower demand.
Schork and other traders don't make much of the EIA report of a big decline in oil inventories last week. They noted that foggy weather and high seas in the Gulf of Mexico, as well as an accident at a southeast Texas port, probably slowed deliveries and account for the drop.
Oil prices are about double what they were a year ago and hit a 15-month high earlier this month even though consumption has been awful. Valero, the nation's biggest refiner, reported Wednesday that it lost almost $2 billion in 2009 as it struggled to pass on higher oil prices to consumers.
Weak has pushed Valero and other refiners to shut some operations.
"Both refinery utilization and crude oil imports are at figures only seen previously after hurricanes, going back over the last two decades or more," Peter Beutel of Cameron Hanover said in a report Wednesday.
After hitting a 15-month high along with oil prices earlier this month, retail gasoline prices continued to slide.
Price fell 0.5 cents Wednesday to a national average of $2.695 per gallon, according to AAA, Wright Express and Oil Price Information Services. Prices are down 4.2 cents in the past week, but remain 9.2 cents above month-ago prices and 85.5 cents higher than prices a year ago.
In other Nymex trading in February contracts, heating oil rose 0.27 cent to $1.9535 a gallon, while gasoline gained 0.45 cent at $1.9719 a gallon. Natural gas futures fell 2.26 cents to $5.259 per 1,000 cubic feet.
In London, Brent crude for March delivery advanced 18 cents to $73.47 a barrel on the ICE Futures exchange.
Associated Press writers Pablo Gorondi in Budapest and Eileen Ng in Kuala Lumpur, Malaysia, contributed to this report.
New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas
Prioritized Pipeline Marks Important Milestone for Company’s New Global R&D Organization
Company Meets Key Late-Stage Development Commitments Made to Investors
Buzz up! 0 Print..Companies:Pfizer Inc..Related Quotes
Symbol Price Change
PFE 18.96 +0.18
{"s" : "pfe","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Pfizer Inc. On Wednesday January 27, 2010, 12:00 pm
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development.
“This pipeline of investigational medicines represents the strong future of Pfizer,” said Martin Mackay, president, PharmaTherapeutics Research and Development. “Since the closing of the Wyeth transaction late last year, we have made strategic decisions about our R&D resources, global footprint and high-priority projects. Our focus now turns to delivery of these health solutions for patients around the world.”
Pfizer has identified six “Invest to Win” areas of research where there exist significant opportunities for innovation and market leadership: oncology; pain; inflammation; Alzheimer’s disease; psychoses; and diabetes. The new pipeline demonstrates focused investment in these areas of significant unmet medical need as well as growth in the critical technologies of vaccines and biologics.
Following the acquisition of Wyeth, the combined company pipeline had 600 projects ranging from discovery through registration. The new prioritized portfolio contains about 500 projects across a broad range of diseases, with a focus on the “Invest to Win” areas, as well as vaccines and biologics. Approximately 70% of Pfizer’s research projects and 75% of the late-stage portfolio are focused on these areas.
The growth in vaccines and biologics is reflective of Pfizer’s goal of becoming a top-tier biotherapeutics company by 2015. The company’s pipeline now includes a total of 6 vaccines and 27 biologics in development, up from 1 vaccine and 16 biologics at the last pipeline update in March 2009.
“Through the acquisition of Wyeth, Pfizer has become a leading biotherapeutics company, and we are well positioned to pioneer the next generation of high-potential medicines,” said Mikael Dolsten, president, BioTherapeutics Research and Development.
Pfizer’s portfolio now includes:
•30 compounds in development for various oncology indications, including PF-02341066, a c-MET-ALK inhibitor in Phase 3 for the treatment of non-small cell lung cancer, and axitinib, a VEGF inhibitor in Phase 2 for lung, gastrointestinal, thyroid, and breast cancer and Phase 3 studies for renal cell carcinoma (RCC). Pfizer has two pan-HER/erbB targeted agents in Phase 3 studies, including PF-00299804 for non-small cell lung cancer and Neratinib for metastatic breast cancer. In addition, Pfizer has therapeutic targets in hematology with compounds in Phase 3 development, such as bosutinib, for the treatment of chronic myelogenous leukemia (CML), in addition to compounds in earlier development, such as inotuzumab ozogamicin for the treatment of Non-Hodgkin’s Lymphoma. Last month, a supplemental new drug application (sNDA) seeking FDA approval for Sutent for the treatment of pancreatic neuroendocrine tumors was filed. Sutent is an oral multi-kinase inhibitor approved for the treatment of advanced / metastatic renal cell carcinoma (RCC) and the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
•10 compounds in development for Alzheimer’s disease, representing a range of mechanisms Pfizer is evaluating for the treatment of this illness. These include Latrepirdine (Dimebon), being developed by Pfizer and Medivation, and bapineuzumab, being developed by Pfizer and Janssen, both in Phase 3 development for the treatment of Alzheimer’s disease.
•8 compounds in development for pain, including tanezumab, a novel injectable biotherapeutic compound which targets nerve growth factor. The Phase 3 program studying tanezumab in osteoarthritis initiated in November, 2008, with more than 5,000 patients planned to be treated with this potential new medicine.
•11 compounds in development for inflammation, including tasocitinib (CP-690,550), Pfizer's JAK-3 inhibitor in development for the treatment of rheumatoid arthritis (RA). Pfizer initiated a global Phase 3 clinical program in RA for tasocitinib (CP-690,550) in February 2009, with five Phase 3 studies ongoing.
•6 vaccines and 27 biologics in the development pipeline, including Prevnar 13, a vaccine designed to prevent pneumococcal disease in infants and young children. Prevnar 13 has been approved for infants and young children in 34 countries, including in the EU and Canada, and is under regulatory review in many other countries, including the U.S. Prevenar 13 is also being studied in global Phase 3 clinical trials in adults, with regulatory submissions expected in 2010.
By the end of 2009, Pfizer as a stand-alone company met three late-stage development commitments made to investors in March 2008. It met a commitment to initiate 10-12 Phase 3 starts between March, 2008 and March, 2009, and it met commitments to initiate 15 Phase 3 starts in the 2008-2009 period and to have 24-28 new molecular entities and new indications in the Phase 3 pipeline by the end of 2009. The new combined company pipeline has 34 new molecular entities and new indications in Phase 3.
Pfizer also announced that it has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Lyrica for the adjunctive treatment of generalized anxiety disorder (GAD).
In November, 2009, Pfizer announced that it would reduce its global R&D square footage by 35 percent. Consequently, R&D activities will be conducted at five main sites and nine specialized units around the world as compared with 20 R&D sites upon closing the acquisition of Wyeth on October 15, 2009.
Detailed information about Pfizer’s pipeline is available at www.pfizer.com/pipeline. Accompanying information includes compound name, target disease, phase of development and, for late-stage programs, mechanism of action.
Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com
DISCLOSURE NOTICE: The information contained in this release is as of January 27, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about various products in development and potential additional indications for certain in-line products, including their potential benefits, and about planned regulatory submissions and planned facility reductions, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications and supplemental drug applications that have been or may be filed for any such products in development and additional indications, as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products and such additional indications; and competitive developments. -6-
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and in its reports on Form 10-Q and Form 8-K.
Contact:
Pfizer Inc.Media:Anne Wilson 212-733-5017 212-733-5017Investor:Suzanne Harnett 212-733-8009
Research and Markets: The Report 'Business to Business Energy Trading' looks At the Leading Market Places In Today's Age, As Well As The Infamous Enron Fiasco
Buzz up! 0 Print..Press Release Source: Research and Markets On Wednesday January 27, 2010, 11:44 am
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/e558eb/business_to_busine) has announced the addition of the "Business to Business Energy Trading" report to their offering.
The energy community is slowly emerging from two decades of obsession with speculation and trading. The era of the energy traders began in the early 1980s, with the deregulation of oil markets by the Reagan and Thatcher administrations, gathered force as Enron and its fellow travelers extended the trading culture to the natural gas and later electricity businesses, and came to an abrupt end in 2002 with the sudden collapse of confidence in many of the premises of the Enron model.
In retrospect, the rise of the energy trader paralleled a national fascination with making gains from an activity that usually operates on the margin of the economy. While every trader with swagger believes he or she will add immense value to an enterprise, with a few notable exceptions, most do not do so. Every experienced trading manager knows that, left to their own devices, most traders will in fact lose money.
This boom in online energy trading has provided a golden opportunity for many companies trading in financial securities to change over to handling energy companies' risk as well. Aruvian Research's report on Business to Business Energy Trading explores all the facets of this fast growing industry and provides a look at what makes up trading of energy exchanges. The report looks at the leading market places in today's age, as well as the infamous Enron fiasco. An analysis of the technologies involved in B2B Energy Trading is also included in the report, along with the basics of energy trading, the process itself, parties involved, and much more. Read on inside to discover more.
Executive Summary:
The energy community is slowly emerging from two decades of obsession with speculation and trading. The era of the energy traders began in the early 1980s, with the deregulation of oil markets by the Reagan and Thatcher administrations, gathered force as Enron and its fellow travelers extended the trading culture to the natural gas and later electricity businesses, and came to an abrupt end in 2002 with the sudden collapse of confidence in many of the premises of the Enron model.
In retrospect, the rise of the energy trader paralleled a national fascination with making gains from an activity that usually operates on the margin of the economy. While every trader with swagger believes he or she will add immense value to an enterprise, with a few notable exceptions, most do not do so. Every experienced trading manager knows that, left to their own devices, most traders will in fact lose money.
The frontier of energy trading remains at the points where natural gas, LNG, oil, and electricity businesses converge. Oil and dry (North American) gas trading are now mature businesses. LNG and electricity trading remain new and challenging. The global energy industry is undergoing dramatic changes with nearly every country going in for deregulation. What has emerged from this is a decoupling of the energy producer and consumer and introduction of an intermediary class of enterprises which deal in energy as a commodity, much like the wholesale grain merchants. And, in accordance with the times, these energy merchants are increasingly conducting their trades through the Internet.
This boom in online energy trading has provided a golden opportunity for many companies trading in financial securities to change over to handling energy companies' risk as well. Aruvian Research's report on Business to Business Energy Trading explores all the facets of this fast growing industry and provides a look at what makes up trading of energy exchanges. The report looks at the leading market places in today's age, as well as the infamous Enron fiasco. An analysis of the technologies involved in B2B Energy Trading is also included in the report, along with the basics of energy trading, the process itself, parties involved, and much more. Read on inside to discover more.
Key Topics Covered:
•Executive Summary
•Introduction to Energy Trading
•Profiling the Industry
•Essentials of Energy Trading
•Hedging & Energy Trading
•Technologies Involved in Energy Trading
•Corporate World & Dynamics of Energy Trading
•Basics of Energy Trading
•Managing the Risk of Energy Trading
•Changing Landscape of Energy Trading
•Leading Market Places
•Outlook for Energy Trading
•Appendix
•Glossary of Terms
•List of Figures & Tables
•Figures
•Tables
Companies Mentioned:
•Energy Data Management (EDM) Pro
•Enermetrix.com
•Utility.com
•HoustonStreet.com
•Essential.com
•Wisconsinpublicservice.com
•Altra Market Place
•The Demand Exchange
•EnronOnline (EOL)
•TradeSpark
•Intercontinental Exchange
•RedMeteor
For more information visit http://www.researchandmarkets.com/research/e558eb/business_to_busine
Contact:
Research and MarketsLaura Wood, Senior Manager,press@researchandmarkets.comU.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
UAL, AirTran results top estimates but shares fall
Buzz up! Print..Companies:Airtran Holdings Inc.Continental Airlines, Inc.Delta Air Lines Inc..On Wednesday January 27, 2010, 12:09 pm
By Karen Jacobs
ATLANTA (Reuters) - U.S. carriers United Airlines and AirTran posted better-than-expected quarterly results on Wednesday, citing improving revenue trends aided in part by returning business travelers.
United parent UAL Corp (NasdaqGS:UAUA - News) posted a smaller quarterly loss as it cut costs to cope with declining travel demand.
"We saw the largest improvements internationally as a result of continued upward trends in premium cabin bookings and corporate travel," UAL Chief Financial Officer Kathryn Mikells said in a staff memo.
Still, UAL shares were down more than 4 percent in noon trade.
Standard & Poor's airline analyst Jim Corridore repeated his "hold" rating, saying UAL still has higher costs than some airlines.
"We see (UAL) shares carrying higher risk than most peers," Corridore said in a note. "While we see the company's cash balance of $3.4 billion as adequate, UAUA does not have much unencumbered assets left, which will make it difficult if it needs to further tap capital markets."
SET FOR RECOVERY
The start of an uptick in business travel points to a better outlook for major U.S. carriers, which have cut jobs and reduced capacity in the past two years as the recession battered demand for flying.
U.S. airlines raised cash in 2009 and now have lower cost structures, said Morningstar analyst Basili Alukos. "In that respect they are all set up for recovery."
The UAL commentary was similar to that from Delta Air Lines Inc (NYSE:DAL - News), which on Tuesday posted a smaller quarterly loss and said its corporate contract bookings were trending up about 10 percent this month from the year ago.
Last week, Continental Airlines (NYSE:CAL - News) and Southwest Airlines (NYSE:LUV - News) posted profits after year-earlier losses and also said business travel was picking up.
PROFIT AT AIRTRAN
AirTran Holdings Inc (NYSE:AAI - News) swung to a profit against a year-earlier loss, and also said it expected unit revenue to improve in February and March after dipping in January. The low-cost carrier also said business markets were trending positive.
At AirTran, net income was $17.1 million, or 11 cents a diluted share, for the fourth quarter, compared with a loss of $121.6 million, or $1.03 a share, a year earlier.
Capacity, measured in available seat miles, was up 8.1 percent, while AirTran traffic, measured by revenue passenger miles, rose 6.9 percent.
UAL said its fourth-quarter net loss narrowed to $240 million, or $1.44 per share, from $1.32 billion, or $10 per share, a year earlier.
Excluding hedge gains and accounting charges, UAL said its quarterly loss was $176 million, or $1.05 a share. On that basis, analysts expected a loss of $1.47 a share, according to Thomson Reuters I/B/E/S.
UAL said consolidated passenger revenue per available seat mile, a key airline measure, fell 5.2 percent in the fourth quarter, an improvement over the third quarter's 14.7 percent drop.
Shares of UAL were down 4.2 percent to $12.25 as other major carriers traded down, while AirTran shares were off 16 cents, or 3.1 percent, to $5.07. Both stocks shed earlier gains after news that new-home sales unexpectedly fell in December pushed the broader market lower.
(Additional reporting by Kyle Peterson in Chicago; Editing by Tim Dobbyn)
Moody's shares rise as analyst sees higher profit
Shares of Moody's rise as analyst upgrades, saying corporate debt offerings will lift profit
Buzz up! 0 Print..Companies:MoodyS Corp..Related Quotes
Symbol Price Change
MCO 28.73 +2.10
{"s" : "mco","k" : "c10,l10,p20,t10","o" : "","j" : ""} On Wednesday January 27, 2010, 12:02 pm
NEW YORK (AP) -- Shares of Moody's Corp. rose nearly 9 percent Wednesday after an analyst wrote that rising corporate debt offerings will lift profits for the ratings agency.
Moody's in October lifted its outlook for the year on continued strength in corporate-debt issuance. It expects profit between $1.60 and $1.68 per share for 2009.
On Wednesday, Benchmark Capital Edward Atorino went slightly further, betting that Moody's fourth-quarter earnings will be 44 cents per share from a previous estimate of 38 cents per share. That suggests annual earnings of $1.70.
Analysts polled by Thomson Reuters see per-share profit of $1.67.
Atorino believes corporate-debt issuance will grow in 2010, and expects strong guidance for next year.
He raised his rating on Moody's to "Buy" from "Hold" and set a $33 price target on the stock.
Moody's shares rose $2.08, or 7.8 percent to $28.70.
Atorino also noted that a federal judge had dismissed claims in a lawsuit against the company related to mortgage-backed securities issued by Lehman Brothers.
Lehman Brothers went bankrupt in Sept. 2008, helping set off a worldwide financial crisis. Its bets on worthless mortgage-backed securities and other real estate assets led to its demise.
The three dominant agencies -- Moody's Investors Service, Standard & Poor's and Fitch Ratings -- have been widely criticized for failing to give investors adequate warning of the risks in subprime mortgage securities.
"This is a positive sign for Moody's as it seeks to get more dismissals in pending litigation," Atorino said.
Stocks edge lower as housing, outlooks weigh
Buzz up! 0 Print..Companies:Dow Jones Industrial AverageDow Jones U.S. Home ConstructioNasdaq Composite.
Reuters - Traders work on the floor of the New York Stock Exchange January 8, 2010. REUTERS/Shannon Stapleton ...
Related Quotes
Symbol Price Change
^DJI 10,176.23 -18.06
^DJUSHB 266.58 +2.15
NASDAQ 2,205.22 +1.49
BA 60.68 +2.97
CAT 52.03 -3.82
{"s" : "^dji,^djushb,^ixic,ba,cat,gild","k" : "c10,l10,p20,t10","o" : "","j" : ""} On Wednesday January 27, 2010, 11:58 am
By Edward Krudy
NEW YORK (Reuters) - The S&P 500 and the Dow fell on Wednesday after a report showed new home sales dropped unexpectedly in December, while Caterpillar Inc (NYSE:CAT - News) and United Technologies Corp (NYSE:UTX - News) gave guarded outlooks for the months ahead.
Investors were also wary before U.S. President Barack Obama's State of the Union speech and the Federal Reserve's policy statement later on Wednesday. The Fed statement may provide clues on how long it will keep in place ultra-low interest rates and its easy-money program.
"There is risk aversion about extending capital into the market place," said Craig Peckham, equity trading strategist at Jefferies & Company in New York. "There is concern about how the language in the (Fed's) statement changes relative to what we saw in December."
The Dow Jones industrial average (DJI:^DJI - News) fell 33.40 points, or 0.33 percent, at 10,160.89. The Standard & Poor's 500 Index (^SPX - News) lost 2.42 points, or 0.22 percent, at 1,089.75. The Nasdaq Composite Index (Nasdaq:^IXIC - News) inched up 0.10 points, or 0.00 percent, at 2,203.83.
New home sales fell for the second straight month, according to the Commerce Department. That weighed on home building stocks such as Pulte Homes Inc (NYSE:PHM - News), which fell 2.4 percent to $10.10. The Dow Jones home construction index (DJI:^DJUSHB - News) fell 0.7 percent.
Caterpillar Inc (NYSE:CAT - News) and United Technologies Corp (NYSE:UTX - News) were the top two drags on the Dow, with Caterpillar shedding 6.3 percent to $52.29, and United Tech off 2 percent to $67.12.
Caterpillar posted stronger-than-expected earnings but forecast 2010 profit below expectations, while United Tech posted a 6 percent drop in quarterly profit and its finance chief warned of a "tough" first quarter.
Obama, in his first State of the Union address, is expected to promise the creation of more jobs and a slimmed budget deficit. The S&P 500 has fallen more than 5 percent over the last week, partly due to political uncertainty surrounding banking regulation.
On the Nasdaq Gilead Sciences Inc (NasdaqGS:GILD - News) and Yahoo Inc (NasdaqGS:YHOO - News) reported stronger-than-expected results late Tuesday. Gilead gained 6.8 percent to $47.90, while Yahoo climbed 1.5 percent to $16.23.
Boeing Co (NYSE:BA - News) was the Dow's top boost, rising 4.1 percent to $59.30 after reporting that it swung to a quarterly profit as revenues soared 42 percent.
(Editing by Kenneth Barry)
Reportlinker Adds The Future of the In-Vitro Diagnostics Market to 2016 - Increasing Diagnostic Procedures Drive Demand
Buzz up! 0 Print..Press Release Source: Reportlinker On Wednesday January 27, 2010, 10:57 am EST
NEW YORK, Jan. 27 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Future of the In-Vitro Diagnostics Market to 2016 - Increasing Diagnostic Procedures Drive Demand
http://www.reportlinker.com/p0174567/The-Future-of-the-In-Vitro-Diagnostics-Market-to-2016---Increasing-Diagnostic-Procedures-Drive-Demand.html
The Future of the In-Vitro Diagnostics Market to 2016 - Increasing Diagnostic Procedures Drive Demand
Summary
GBI Research's new report, "The Future of the In-Vitro Diagnostics Market to 2016 - Increasing Diagnostic Procedures Drive Demand" provides key data, information and analysis on the global in-vitro diagnostics market, a key segment within the medical equipment industry. This medical device report provides market landscape, competitive landscape and market trends information on seven in-vitro diagnostics market categories - Clinical Chemistry, Genetic Testing, Histology and Cytology, Immuno Chemistry, Infectious Immunology, Microbiology Culture and Haematology. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Scope
- Key geographies including the US (United States), Canada, the UK (United Kingdom), Germany, France, Italy, Spain, Belgium, Netherlands, Japan, China, India, Australia, Taiwan, republic of Korea, Brazil, Argentina, Mexico, Israel and South Africa.
- Global Market size and company share data for seven In-Vitro Diagnostics market categories – clinical chemistry, genetic testing, histology and cytology, immuno chemistry, infectious immunology, microbiology culture and haematology.
- Annualized market revenues data from 2002 to 2009, forecast forward for 7 years to 2016. Company shares data for 2008.
- Qualitative analysis of key market trends, market drivers and restraints by categories and segments.
- Competitive landscape and key company profiles. Key players covered include Roche, Siemens Healthcare, Abbott, Beckman Coulter, Biomerieux, Ortho-Clinical Diagnostics, Becton, Dickinson (BD), Bio-Rad Laboratories, Inverness Medical Innovations, Sysmex, Gen-Probe and Dade Behring.
- Key in-pipeline products and technologies expected to hit the global In-Vitro Diagnostics market in the near future.
Reasons to buy
- Develop business strategies by understanding the trends and developments that are driving the In-Vitro Diagnostics market globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline. Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What's the next big thing in the In-Vitro Diagnostics market landscape? – Identify, understand and capitalize
- Make more informed business decisions from the insightful and in-depth analysis of the In-Vitro Diagnostics market and the factors shaping it.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures Introduction and Overview 11
2.1 In-Vitro Diagnostics Overview 11
3 Global IVD Market: Market Characterization 12
3.1 Global IVD Market, Revenues ($m), 2002 – 2009 12
3.2 Global IVD Market, Revenue Forecasts ($m), 2009 – 2016 13
3.3 Global IVD Market, Key Company Shares (%), 2008 14
3.4 Global In-vitro Devices, Key Market Trends 15
3.4.1 Entry of In Diagnostic Imaging Players Into In Vitro Diagnostics Market Has Set Stage for New Technologies to Be Developed By Marrying the Two Disciplines 15
3.4.2 Large Number of Private Equity/ Venture Capital (PE/VC) Investments and Collaborations in the IVD Sector to Fuel Innovation 16
3.4.3 Consolidation of Laboratories across the World 16
3.5 Global In Vitro Diagnostics: Key Technology Trends 17
3.5.1 Emerging technologies for cutting lab costs 17
3.5.2 New Technologies Improve Speed and Accuracy 18
3.6 Global In-vitro Devices, Market Drivers 20
3.6.1 Economic Market Drivers 20
3.6.2 Technology Market Drivers 22
3.6.3 Regulatory Market Drivers 22
3.6.4 Social Market Drivers 22
3.7 In-vitro Devices, Market Restraints 23
3.7.1 Economic Market Restraints 23
3.7.2 Social Market Restraints 24
4 Global IVD Market: Market Category Analysis and Forecasts 25
4.1 Clinical Chemistry Market: Market Characterization 25
4.1.1 Global Clinical Chemistry Market, Revenues ($m), 2002–2009 25
4.1.2 Global Clinical Chemistry Market, Revenue Forecasts ($m), 2009–2016 26
4.1.3 Global Clinical Chemistry Market, Key Company Shares (%), 2008 27
4.1.4 Clinical Chemistry Market: Market Drivers 28
4.1.5 Clinical Chemistry Market: Market Restraints 29
4.2 Immuno Chemistry Market: Market Characterization 30
4.2.1 Global Immuno Chemistry Market, Revenues ($m), 2002 – 2009 30
4.2.2 Global Immuno Chemistry Market, Revenue Forecasts ($m), 2009 – 2016 31
4.2.3 Global Immuno Chemistry Market, Key Company Shares (%), 2008 32
4.2.4 Immuno Chemistry Market: Market Drivers 33
4.2.5 Immuno Chemistry Market: Market Restraints 35
4.3 Haematology Market: Market Characterization 36
4.3.1 Global Haematology Market, Revenues ($m), 2002 – 2009 36
4.3.2 Global Haematology Market, Revenue Forecasts ($m), 2009 – 2016 37
4.3.3 Global Haematology Market, Key Company Shares (%), 2008 38
4.3.4 Haematology Market: Market Drivers 39
4.3.5 Haematology Market: Market Restraints 40
4.4 Histology and Cytology Market: Market Characterization 41
4.4.1 Global Histology and Cytology Market, Revenue ($m), 2002 – 2009 41
4.4.2 Global Histology and Cytology Market, Revenue Forecasts ($m), 2009 – 2016 42
4.4.3 Global Histology and Cytology Market, Key Company Shares (%), 2008 43
4.4.4 Histology and Cytology Market: Market Drivers 44
4.4.5 Histology and Cytology Market: Market Restraints 45
4.5 Microbiology Culture Market: Market Characterization 46
4.5.1 Global Microbiology Culture Market, Revenues ($m), 2002 – 2009 46
4.5.2 Global Microbiology Culture Market, Revenue Forecasts ($m), 2009 – 2016 47
4.5.3 Global Microbiology Culture Market, Key Company Shares (%), 2008 48
4.5.4 Global Microbiology Culture Market: Market Drivers 49
4.5.5 Global Market Restraints Microbiology Culture Market: Market Restraints 50
4.6 Infectious Immunology Market: Market Characterization 51
4.6.1 Global Infectious Immunology Market, Revenues ($m), 2002 – 2009 51
4.6.2 Global Infectious Immunology Market, Revenue Forecasts ($m), 2009 – 2016 52
4.6.3 Global Infectious Immunology Market, Key Company Shares (%), 2008 53
4.6.4 Global Infectious Immunology Market: Market Drivers 53
4.6.5 Global Infectious Immunology Market: Market Restraints 54
4.7 Genetic Testing Market: Market Characterization 55
4.7.1 Global Genetic Testing Market, Revenues ($m), 2002 – 2009 55
4.7.2 Global Genetic Testing Market, Key Company Shares (%), 2008 57
4.7.3 Global Genetic Testing Market: Market Drivers 58
4.7.4 Global Genetic Testing Market: Market Restraints 59
5 Global IVD Market: Country Analysis and Forecasts 61
5.1 Global IVD Market: Geographic Trends Analysis 61
5.2 Market Characterization, North America, 2002 – 2016 62
5.2.1 The US IVD Market, Revenues ($m), 2002 – 2009 62
5.2.2 The US IVD Market, Revenues ($m), 2009 – 2016 63
5.2.3 Canada IVD Market, Revenues ($m), 2002 – 2009 64
5.2.4 North America IVD Market, Market Drivers 66
5.2.5 North America IVD Market, Market Restraints 66
5.3 Market Characterization, Europe, 2002 – 2016 67
5.3.1 The UK IVD Market, Revenues ($m), 2002 – 2009 67
5.3.2 The UK IVD Market, Revenues ($m), 2009 – 2016 68
5.3.3 Germany IVD Market, Revenues ($m), 2002 – 2009 69
5.3.4 Germany IVD Market, Revenues ($m), 2009 – 2016 70
5.3.5 France IVD Market, Revenues ($m), 2002 – 2009 71
5.3.6 France IVD Market, Revenues ($m), 2009 – 2016 73
5.3.7 Italy IVD Market, Revenues ($m), 2002 – 2009 74
5.3.8 Italy IVD Market, Revenues ($m), 2009 – 2016 75
5.3.9 Spain IVD Market, Revenues ($m), 2002 – 2009 76
5.3.10 Spain IVD Market, Revenues ($m), 2009 – 2016 77
5.3.11 Belgium IVD Market, Revenues ($m), 2002 – 2009 78
5.3.12 Belgium IVD Market, Revenues ($m), 2009 – 2016 79
5.3.13 The Netherlands IVD Market, Revenues ($m), 2002 – 2009 80
5.3.14 The Netherlands IVD Market, Revenues ($m), 2009 – 2016 81
5.3.15 Europe IVD Market, Market Drivers 81
5.3.16 Europe IVD Market, Market Restraints 82
5.4 Market Characterization, Asia Pacific, 2002 – 2016 83
5.4.1 Japan IVD Market, Revenues ($m), 2002 – 2009 83
5.4.2 Japan IVD Market, Revenues ($m), 2009 – 2016 84
5.4.3 China IVD Market, Revenues ($m), 2002 – 2009 85
5.4.4 China IVD Market, Revenues ($m), 2009 – 2016 86
5.4.5 India IVD Market, Revenues ($m), 2002 – 2009 87
5.4.6 India IVD Market, Revenues ($m), 2009 – 2016 88
5.4.7 Australia IVD Market, Revenues ($m), 2002 – 2009 90
5.4.8 Australia IVD Market, Revenues ($m), 2009 – 2016 91
5.4.9 Taiwan IVD Market, Revenues ($m), 2002 – 2009 92
5.4.10 Taiwan IVD Market, Revenues ($m), 2009 – 2016 93
5.4.11 Republic of Korea IVD Market, Revenues ($m), 2002 – 2009 94
5.4.12 Republic of Korea IVD Market, Revenues ($m), 2009 – 2016 95
5.4.13 Asia Pacific IVD Market, Market Drivers 96
5.4.14 Asia Pacific IVD Market, Market Restraints 96
5.5 Market Characterization, South and Central America, 2002 – 2016 97
5.5.1 Brazil IVD Market, Revenues ($m), 2002 – 2009 97
5.5.2 Brazil IVD Market, Revenues ($m), 2009 – 2016 98
5.5.3 Argentina IVD Market, Revenues ($m), 2002 – 2009 99
5.5.4 Argentina IVD Market, Revenues ($m), 2009 – 2016 100
5.5.5 Mexico IVD Market, Revenues ($m), 2002 – 2009 101
5.5.6 Mexico IVD Market, Revenues ($m), 2009 – 2016 102
5.5.7 South and Central America IVD Market, Market Drivers 103
5.5.8 South and Central America IVD Market, Market Restraints 103
5.6 Market Characterization, Middle East and Africa, 2002 – 2016 104
5.6.1 Israel IVD Market, Revenues ($m), 2002 – 2009 104
5.6.2 Israel IVD Market, Revenues ($m), 2009 – 2016 105
5.6.3 South Africa IVD Market, Revenues ($m), 2002 – 2009 106
5.6.4 South Africa IVD Market, Revenues ($m), 2009 – 2016 107
5.6.5 Middle East and Africa IVD Market, Market Drivers 108
5.6.6 Middle East and Africa IVD Market, Market Restraints 108
6 Global IVD Market: Strategic Competitive Assessment 109
6.1 Key Market Participants 109
6.1.1 F. Hoffmann-La Roche Ltd 109
6.1.2 Siemens Medical Solutions USA, Inc. 111
6.1.3 Abbott Laboratories 113
6.1.4 Beckman Coulter, Inc. 115
6.1.5 bioMerieux Sa 117
6.1.6 Ortho-Clinical Diagnostics 118
6.1.7 Becton, Dickinson and Company 119
6.1.8 Bio-Rad Laboratories, Inc. 120
6.1.9 Inverness Medical Innovations, Inc 121
7 Global IVD Market: Product Pipeline Analysis 124
7.1 Pipeline Products Analysis by Category 124
7.1.1 Pipeline Products Analysis: Immuno Chemistry Market 125
7.1.2 Pipeline Products Analysis: Infectious Immunology 126
7.2 Key Pipeline Products Currently Undergoing Development 126
7.2.1 Clinical Chemistry Pipeline Products 126
7.2.2 Genetic Testing 126
7.2.3 Haematology 127
7.2.4 Immunochemistry 128
7.2.5 Infectious Immunology 129
7.2.6 Microbiology Culture 130
7.2.7 Histology and Cytology 130
8 Global IVD Market: Consolidation Landscape 131
8.1 Deals by Type, 2006 – 2009 131
8.2 Deals by Value and Volume, 2006 – 2009 132
8.3 List of Deals in 2009 132
8.4 Top 10 Acquisitions By Value, 2009 135
8.4.1 Agilent Technologies Receives Shareholders Approval To Acquire Varian 135
8.4.2 Beckman Coulter Completes Acquisition Of Olympus-DS From OLYMPUS 135
8.4.3 MDS Receives Shareholder Approval To Sell MDS Analytical Technologies To Danaher 135
8.4.4 Thermo Fisher Scientific Completes Acquisition Of B.R.A.H.M.S. 136
8.4.5 Corning Acquires Axygen BioScience And Its Subsidiaries From American Capital 136
8.4.6 Becton, Dickinson and Company Completes Acquisition Of HandyLab 136
8.4.7 Inverness Medical Innovations Completes Acquisition Of Concateno From Marwyn 137
8.4.8 Laboratory Corporation of America Holdings Completes Acquisition Of Monogram Biosciences 137
8.4.9 Gen-Probe Acquires Tepnel Life Sciences 137
9 Appendix 139
9.1 Definitions 139
9.1.1 Clinical Chemistry 139
9.1.2 Immunochemistry Test Reagents 140
9.1.3 Haematology 141
9.1.4 Histology And Cytology 142
9.1.5 Microbiology Culture 143
9.1.6 Infectious Immunology 143
9.1.7 Genetic Testing 144
9.2 Acronyms 144
9.3 Methodology 144
9.3.1 Secondary Research 145
9.3.2 Primary Research 145
9.3.3 Models 146
9.3.4 Forecasts 146
9.3.5 Expert Panels 146
9.4 Contact Us 146
9.5 Disclaimer 147
1.1 List of Tables
Table 1: IVD Market, Global, Revenue ($m), 2002-2009 12
Table 2: IVD Market, Global, Revenue ($m), 2009-2016 13
Table 3: IVD Market, Global, Company Share ($m), 2008 14
Table 4: Clinical Chemistry Market, Global, Revenues ($m), 2002–2009 25
Table 5: Clinical Chemistry Market, Global, Revenue ($m), 2009–2016 26
Table 6: Clinical Chemistry Market, Global, Company Share ($m), 2008 27
Table 7: Clinical Chemistry Market, Comparison of Top 10 Countries By Revenue, 2002–2016 28
Table 8: Immuno Chemistry Market, Global, Revenues ($m), 2002–2009 30
Table 9: Immuno Chemistry Market, Global, Revenue ($m), 2009–2016 32
Table 10: Immuno Chemistry Market, Global, Company Share ($m),2008 33
Table 11: Immuno Chemistry Market, Comparison of Top 10 Countries By Revenue, 2002–2016 34
Table 12: Haematology Market, Global, Revenues ($m), 2002–2009 36
Table 13: Haematology Market, Global, Revenue ($m), 2009–2016 37
Table 14: Haematology Market, Global, Company Share ($m),2008 38
Table 15: Haematology Market, Comparison of Top 10 Countries By Revenue, 2002–2016 39
Table 16: Histology and Cytology Market, Global, Revenue ($m), 2002–2009 41
Table 17: Histology and Cytology Market, Global, Revenue ($m), 2009–2016 42
Table 18: Histology and Cytology Market, Global, Company Share ($m),2008 43
Table 19: Histology and Cytology Market, Comparison of Top 10 Countries By Revenue,
2002–2016 44
Table 20: Microbiology Culture Market, Global, Revenue ($m), 2002–2009 46
Table 21: Microbiology Culture Market, Global, Revenue ($m), 2009–2016 47
Table 22: Microbiology Culture Market, Global, Company Share ($m),2008 48
Table 23: Microbiology Culture Market, Comparison of Top 10 Countries By Revenue,
2002–2016 49
Table 24: Infectious Immunology Market, Global, Revenue ($m), 2002–2009 51
Table 25: Infectious Immunology Market, Global, Revenue ($m), 2009–2016 52
Table 26: Infectious Immunology Market, Global, Company Share ($m),2008 53
Table 27: Genetic Testing Market, Global, Revenue ($m), 2002–2009 55
Table 28: Genetic Testing Market, Global, Revenue ($m), 2009–2016 56
Table 29: Global Genetic Testing Market, Global, Company Share ($m),2008 57
Table 30: Genetic Testing Market, Comparison of Top 10 Countries By Revenue, 2002–2016 58
Table 31: IVD Market, US, Revenue ($m), 2002-2009 62
Table 32: IVD Market, US, Revenue ($m), 2009-2016 63
Table 33: IVD Market, Canada, Revenue ($m), 2002-2009 64
Table 34: IVD Market, Canada, Revenue ($m), 2009-2016 65
Table 35: IVD Market, The UK, Revenue ($m), 2002-2009 67
Table 36: IVD Market, The UK, Revenue ($m), 2009-2016 68
Table 37: IVD Market, Germany, Revenue ($m), 2002-2009 69
Table 38: IVD Market, Germany, Revenue ($m), 2009-2016 70
Table 39: IVD Market, France, Revenue ($m), 2002-2009 72
Table 40: IVD Market, France, Revenue ($m), 2009-2016 73
Table 41: IVD Market, Italy, Revenue ($m), 2002-2009 74
Table 42: IVD Market, Italy, Revenue ($m), 2009-2016 75
Table 43: IVD Market, Spain, Revenue ($m), 2002-2009 76
Table 44: IVD Market, Spain, Revenue ($m), 2009-2016 77
Table 45: IVD Market, Belgium, Revenue ($m), 2002-2009 78
Table 46: IVD Market, Belgium, Revenue ($m), 2009-2016 79
Table 47: IVD Market, The Netherlands, Revenue ($m), 2002-2009 80
Table 48: IVD Market, The Netherlands, Revenue ($m), 2009-2016 81
Table 49: IVD Market, Japan, Revenue ($m), 2002-2009 83
Table 50: IVD Market, Japan, Revenue ($m), 2009-2016 84
Table 51: IVD Market, China, Revenue ($m), 2002-2009 85
Table 52: IVD Market, China, Revenue ($m), 2009-2016 86
Table 53: IVD Market, India, Revenue ($m), 2002-2009 88
Table 54: IVD Market, India, Revenue ($m), 2002-2009 89
Table 55: IVD Market, Australia, Revenue ($m), 2002-2009 90
Table 56: IVD Market, Australia, Revenue ($m), 2009-2016 91
Table 57: IVD Market, Taiwan, Revenue ($m), 2002-2009 92
Table 58: IVD Market, Taiwan, Revenue ($m), 2009-2016 93
Table 59: IVD Market, Republic of Korea, Revenue ($m), 2002-2009 94
Table 60: IVD Market, Republic of Korea, Revenue ($m), 2009-2016 95
Table 61: IVD Market, Brazil, Revenue ($m), 2002-2009 97
Table 62: IVD Market, Brazil, Revenue ($m), 2009-2016 98
Table 63: IVD Market, Argentina, Revenue ($m), 2002-2009 99
Table 64: IVD Market, Argentina, Revenue ($m), 2009-2016 100
Table 65: IVD Market, Mexico, Revenue ($m), 2002-2009 101
Table 66: IVD Market, Mexico, Revenue ($m), 2009-2016 102
Table 67: IVD Market, Israel, Revenue ($m), 2002-2009 104
Table 68: IVD Market, Israel, Revenue ($m), 2009-2016 105
Table 69: IVD Market, South Africa, Revenue ($m), 2002-2009 106
Table 70: IVD Market, South Africa, Revenue ($m), 2009-2016 107
Table 71: Roche's Merger and Acquisitions, IVD Market, 2007–2009 109
Table 72: Roche IVD Pipeline Product Portfolio 110
Table 73: Siemens Medical Solutions IVD Pipeline Product Portfolio 112
Table 74: Siemen's Merger and Acquisitions, IVD Market, 2007–2009 113
Table 75: Abbott Laboratories' Mergers and Acquisitions, IVD Market, 2007–2009 114
Table 76: Abbott Laboratories IVD Pipeline Products 114
Table 77: Beckman Coulter's Mergers and Acquisitions, IVD Market, 2007–2009 116
Table 78: Beckman Coulter, Inc. IVD Pipeline Products 117
Table 79: bioMerieux's Mergers and Acquisitions, IVD Market, 2007–2009 118
Table 80: bioMerieux Sa IVD Pipeline Products 118
Table 81: Ortho-Clinical Diagnostics, IVD Pipeline Products 119
Table 82: Becton Dickinson, Mergers and Acquisitions, IVD Market, 2007–2009 120
Table 83: Becton, Dickinson Inc. IVD Pipeline Portfolio 120
Table 84: Bio-Rad, Merger and Acquisitions, IVD Market, 2007–2009 121
Table 85: Inverness Medical Innovations, Inc., Mergers and Acquisitions, IVD Market, 2007–2009 122
Table 86: Inverness Medical Innovations IVD Pipeline Portfolio 123
Table 87: IVD Market, Global, Pipeline Products by Category, 2009 124
Table 88: Immuno Chemistry Market, Global, Pipeline Products Analysis, 2009 125
Table 89: Infectious Immunology Market, Global, 2009 126
Table 90: Deals By Type, Global IVD Market, 2006-2009 131
Table 91: Key Deals, Global IVD Market, 2009 132
1.2 List of Figures
Figure 1: IVD Market, Global, Revenue ($m), 2002-2009 12
Figure 2: IVD Market, Global, Revenue ($m), 2009-2016 13
Figure 3: IVD Market, Global, Company Share (%),2008 14
Figure 4: Global In-vitro Devices: Key Market Trends 15
Figure 5: Global Laboratory Consolidation Landscape, 2005–2009 16
Figure 6: Global In Vitro Diagnostics: Key Technology Trends 17
Figure 7: Global In Vitro Diagnostics: Market Drivers and Restraints 19
Figure 8: List of Retail Clinics in the US and Diagnostic IVD Tests Offered 21
Figure 9: Clinical Chemistry Market, Global, Revenues ($m), 2002–2009 25
Figure 10: Clinical Chemistry Market, Global, Revenue ($m), 2009–2016 26
Figure 11: Clinical Chemistry Market, Global, Company Share (%),2008 27
Figure 12: Clinical Chemistry Market, Comparison of Top 10 Countries By Revenue, 2002–2016 28
Figure 13: Immuno Chemistry Market, Global, Revenues ($m), 2002–2009 30
Figure 14: Immuno Chemistry Market, Global, Revenue ($m), 2009–2016 31
Figure 15: Immuno Chemistry Market, Global, Company Share (%),2008 32
Figure 16: Immuno Chemistry Market, Comparison of Top 10 Countries By Revenue, 2002–2016 33
Figure 17: Haematology Market, Global, Revenues ($m), 2002–2009 36
Figure 18: Haematology Market, Global, Revenue ($m), 2009–2016 37
Figure 19: Haematology Market, Global, Company Share (%),2008 38
Figure 20: Haematology Market, Comparison of Top 11 Countries By Revenue, 2002–2016 39
Figure 21: Histology and Cytology Market, Global, Revenue ($m), 2002–2009 41
Figure 22: Histology and Cytology Market, Global, Revenue ($m), 2009–2016 42
Figure 23: Histology and Cytology Market, Global, Company Share (%),2008 43
Figure 24: Histology and Cytology Market, Comparison of Top 10 Countries By Revenue,
2002–2016 44
Figure 25: Microbiology Culture Market, Global, Revenue ($m), 2002–2009 46
Figure 26: Microbiology Culture Market, Global, Revenue ($m), 2009–2016 47
Figure 27: Microbiology Market, Global, Company Share (%),2008 48
Figure 28: Microbiology Culture Market, Comparison of Top 10 Countries By Revenue,
2002–2016 49
Figure 29: Infectious Immunology Market, Global, Revenue ($m), 2002–2009 51
Figure 30: Infectious Immunology Market, Global, Revenue ($m), 2009–2016 52
Figure 31: Infectious Immunology Market, Global, Company Share (%),2008 53
Figure 32: Genetic Testing Market, Global, Revenue ($m), 2002–2009 55
Figure 33: Genetic Testing Market, Global, Revenue ($m), 2009–2016 56
Figure 34: Global Genetic Testing Market, Global, Company Share (%),2008 57
Figure 35: Genetic Testing Market, Comparison of Top 10 Countries By Revenue, 2002–2016 58
Figure 36: IVD Market, Global, Geographic Trends Analysis 61
Figure 37: IVD Market, US, Revenue ($m), 2002-2009 62
Figure 38: IVD Market, US, Revenue ($m), 2009-2016 63
Figure 39: IVD Market, Canada, Revenue ($m), 2002-2009 64
Figure 40: IVD Market, Canada, Revenue ($m), 2009-2016 65
Figure 41: IVD Market, The UK, Revenue ($m), 2002-2009 67
Figure 42: IVD Market, The UK, Revenue ($m), 2009-2016 68
Figure 43: IVD Market, Germany, Revenue ($m), 2002-2009 69
Figure 44: IVD Market, Germany, Revenue ($m), 2009-2016 70
Figure 45: IVD Market, France, Revenue ($m), 2002-2009 71
Figure 46: IVD Market, France, Revenue ($m), 2009-2016 73
Figure 47: IVD Market, Italy, Revenue ($m), 2002-2009 74
Figure 48: IVD Market, Italy, Revenue ($m), 2009-2016 75
Figure 49: IVD Market, Spain, Revenue ($m), 2002-2009 76
Figure 50: IVD Market, Spain, Revenue ($m), 2009-2016 77
Figure 51: IVD Market, Belgium, Revenue ($m), 2002-2009 78
Figure 52: IVD Market, Belgium, Revenue ($m), 2009-2016 79
Figure 53: IVD Market, The Netherlands, Revenue ($m), 2002-2009 80
Figure 54: IVD Market, The Netherlands, Revenue ($m), 2009-2016 81
Figure 55: IVD Market, Japan, Revenue ($m), 2002-2009 83
Figure 56: IVD Market, Japan, Revenue ($m), 2009-2016 84
Figure 57: IVD Market, China, Revenue ($m), 2002-2009 85
Figure 58: IVD Market, China, Revenue ($m), 2009-2016 86
Figure 59: IVD Market, India, Revenue ($m), 2002-2009 87
Figure 60: IVD Market, India, Revenue ($m), 2002-2009 88
Figure 61: IVD Market, Australia, Revenue ($m), 2002-2009 90
Figure 62: IVD Market, Australia, Revenue ($m), 2009-2016 91
Figure 63: IVD Market, Taiwan, Revenue ($m), 2002-2009 92
Figure 64: IVD Market, Taiwan, Revenue ($m), 2009-2016 93
Figure 65: IVD Market, Republic of Korea, Revenue ($m), 2002-2009 94
Figure 66: IVD Market, Republic of Korea, Revenue ($m), 2009-2016 95
Figure 67: IVD Market, Brazil, Revenue ($m), 2002-2009 97
Figure 68: IVD Market, Brazil, Revenue ($m), 2009-2016 98
Figure 69: IVD Market, Argentina, Revenue ($m), 2002-2009 99
Figure 70: IVD Market, Argentina, Revenue ($m), 2009-2016 100
Figure 71: IVD Market, Mexico, Revenue ($m), 2002-2009 101
Figure 72: IVD Market, Mexico, Revenue ($m), 2009-2016 102
Figure 73: IVD Market, Israel, Revenue ($m), 2002-2009 104
Figure 74: IVD Market, Israel, Revenue ($m), 2009-2016 105
Figure 75: IVD Market, South Africa, Revenue ($m), 2002-2009 106
Figure 76: IVD Market, South Africa, Revenue ($m), 2009-2016 107
Figure 77: IVD Market, Global, Pipeline Products Analysis by Category, 2009 124
Figure 78: Immuno Chemistry Market, Global, Pipeline Products Analysis, 2009 125
Figure 79: Infectious Immunology Market, Global, 2009 126
Figure 80: Deals By Type, Global IVD Market, 2006-2009 131
Figure 81: Deals By Value and Volume, Global IVD Market, Value ($m), 2006-2009 132
Figure 82: GBI Research Methodology 145
Companies Mentioned
F. Hoffmann-La Roche Ltd
Siemens Medical Solutions USA, Inc.
Abbott Laboratories
Beckman Coulter, Inc
bioMerieux Sa
Ortho-Clinical Diagnostics
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Inverness Medical Innovations, Inc
To order this report:
In Vitro Diagnostic Industry: The Future of the In-Vitro Diagnostics Market to 2016 - Increasing Diagnostic Procedures Drive Demand
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626 (805)652-2626
Intl: +1 805-652-2626 +1 805-652-2626
Reportlinker Adds Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs
Buzz up! 0 Print..Press Release Source: Reportlinker On Wednesday January 27, 2010, 10:15 am EST
NEW YORK, Jan. 27 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs
http://www.reportlinker.com/p0174572/Biomarkers-in-Drug-Discovery---Optimizing-Drug-Discovery-Timeline-and-Costs.html
Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs
Summary
GBI Research, the leading business intelligence provider, has released its latest research, "Biomarkers In Drug Discovery - Optimizing Drug Discovery Timeline and Costs." The report provides an in-depth analysis of the potential applications of biomarkers in pharmaceutical drug discovery and clinical services. This pharmaceutical and healthcare report suggests investment decisions in biomarker-based drug research by providing information on valid biomarkers, pipelines, case studies, competitive landscape, geographical trends, mergers and acquisitions and market potential. It also provides an analysis on the trends prevailing in the global biomarkers market. In addition to this, the report covers drivers and restrains for the global biomarkers market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Scope
The scope of this report includes:
- Market Potential and Pipeline Analysis of biomarkers by phase of development, therapeutic class and geography.
- Market Size and forecast of global biomarkers market and biomarkers drug discovery market from 2000 to 2008, forecast forward to 2015.
- Analysis of Key geographies including the US (United States), Europe the UK (United Kingdom), France, Germany, Italy and Spain), Australia and Southeast Asia.
- Investments and Funding Analysis for top companies (Quest Diagnostics, Applied Biosystems, Vermillion, BGMedical, Menarini, Abbott, Roche, Genetech, Affymetrix and Amgen) in the biomarker-based assay development arena. This includes biomarker research on the application and development of novel biomarkers by the top companies and analysis of the competitive factors affecting the global biomarkers market.
- Qualitative analysis of market drivers, market trends, and challenges.
- M&A landscape in the biomarkers space segmented by deal value, geography and phase.
Reasons to buy
The report will improve decision making and will enable you to:
- Develop business strategies by understanding the trends and developments that are driving the biomarkers-based drug research and development.
- Design, develop and expand your product development, marketing and sales strategies based on forecast of global biomarkers and biomarkers drug discovery market till 2015
- Develop business strategies to exploit biomarkers-based drug discovery market in emerging geographies
- Identify the key players positioned to take advantage of the emerging market opportunities
- Exploit M&A opportunities by identifying key market players with the most novel pipeline
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Biomarkers in Drug Discovery - Facilitating a Quick Turnaround Time: Overview 8
2.1 Introduction 8
2.2 GBI Research Report Guidance 8
2.3 History of Biomarkers 9
2.4 Biomarker Discovery and the Validation Process 10
2.4.1 Product Development Process from Discovery to Launch 11
2.5 General Application of Biomarkers 12
2.5.1 Biomarkers in Drug Discovery and Drug Development 13
2.5.2 Role of Biomarkers in the Drug Discovery Process 13
2.5.3 Application of Biomarkers in Disease Diagnosis and Prognosis 13
2.5.4 Potential Impact of Biomarkers on Disease States 15
2.5.5 Population Genetics Study 15
2.5.6 Environmental Health and Risk Assessment 17
2.5.7 Role of Biomarkers in Environmental Health and Risk Assessment 17
2.5.8 Toxicology Studies in Dietary Items or Nutraceuticals 18
2.6 Application of Biomarkers in Drug Discovery 18
2.6.1 Lead Identification & Optimization 19
2.6.2 Potential Role of Biomarkers in Lead Identification and Optimization 19
2.6.3 Target Validation 20
2.6.4 Toxicological Assay (Preclinical & Clinical) 20
2.6.5 Mechanism of Action 20
2.6.6 Monitor Therapy and Dose Response 21
2.6.7 Stratify Patient Population 21
2.6.8 Filing and Post Marketing Surveillance 21
3 Biomarkers in Drug Discovery - Case Studies 23
3.1 Vermillion's Hepcidin Biomarker for Ovarian Oancer 23
3.1.1 Definition 23
3.1.2 Hepcidin Biomarker 23
3.1.3 About Ovarian Cancer 23
3.1.4 Company Profile 24
3.1.5 Technology Used 25
3.1.6 Market Information 25
3.1.7 Advantages 25
3.1.8 Future Prospect 26
3.2 Epigenomic's Septin 9 Biomarker for Colorectal Cancer 26
3.2.1 DNA Methylation 26
3.2.2 Septin 9 27
3.2.3 Septin Biomarker 27
3.2.4 About Colorectal Cancer 27
3.2.5 Advantages 27
3.2.6 Future Perspective 28
3.2.7 Clinical Study 28
3.2.8 Company Profile 28
3.2.9 Technology Overview 29
3.2.10 Market Information 29
3.3 BiPar Science's PARP 1 Gene Biomarker for Multiple Cancer Types 29
3.3.1 PARP 1 Gene 29
3.3.2 PARP 1 Inhibitors 30
3.3.3 BSI-201 30
3.3.4 TNBC (Triple Negative Breast Cancer) 31
3.3.5 Technology 31
3.3.6 Advantage 31
3.3.7 Company Profile 31
3.3.8 Market Information 31
3.3.9 Clinical Study 31
4 Biomarkers in Drug Discovery – Market Characterization 33
4.1 Market Overview 33
4.2 Market Size and Forecasts 33
4.2.1 Driver and Restraints 37
4.2.2 Drivers for the Global Biomarkers Market 38
4.2.3 Barriers for the Global Biomarkers Market 40
4.3 Unmet Needs - Biomarkers Fulfilling the Unmet Needs of Drug Discovery 40
4.3.1 High Attrition Rates 41
4.3.2 High Drug Discovery Cost 41
4.3.3 Time consuming 42
4.3.4 Safety and Efficacy 42
4.3.5 Invasiveness, Selectivity and Sensitivity 42
5 Trends Analysis 43
5.1 Regulatory Landscape (Current and Future) 43
5.1.1 Investigative/ Exploratory Biomarker 43
5.1.2 Probable Valid Biomarker 43
5.1.3 Known Valid Biomarker 43
5.1.4 Regulatory Biomarker 43
5.2 Validated Biomarker 43
5.2.1 Validated Biomarkers Applied by Top Pharmaceuticals Players in their FDA Approved Drugs 44
5.3 Regulatory Acceptance of Valid Biomarkers 45
5.4 Regulatory Guidance from the FDA, EMEA, and MHLW (Japan) 46
6 Technology Adoptions 47
6.1 Unmet Need - Drug Discovery 47
6.1.1 Biomarkers Technology Exists to Fulfill Unmet Drug Discovery Needs 47
6.2 Increased Awareness Among Pharmaceutical and Research Sector 48
6.3 Increasing Adoption Due to Wide Application 48
6.4 Biomarkers' Future - Drug Discovery Unmet Needs Fulfilled 48
7 Global Biomarkers Market– Competitive Landscape 49
7.1 Key Biomarkers Players 49
7.1.1 Quest Diagnostics 50
7.1.2 Applied Biosystems 51
7.1.3 Vermillion 52
7.1.4 BGMedical 53
7.1.5 Menarini 54
7.1.6 Abbott 55
7.1.7 Roche 56
7.1.8 Genentech 57
7.1.9 Affymetrix 58
7.1.10 Amgen 59
7.2 Global Biomarkers Market – Geographic Landscape 60
8 Biomarkers in Drug Discovery – Pipeline Analysis 62
8.1 Pipeline Analysis 62
8.1.1 Pipeline analysis by Phase 65
8.1.2 Pipeline Analysis – Therapeutic class 66
8.1.3 Pipeline Analysis by Geography 67
9 Global Biomarkers market – Strategic Consolidations 68
9.1 Mergers and Acquisitions 68
9.1.1 Thermo Fisher Scientific Inc. Merges with B.R.A.H.M.S. AG 68
9.1.2 Clinical Data Inc to Acquire Avlon Pharmaceuticals 68
9.1.3 OSI Pharmaceuticals and AVEO Enter Collaborative Alliance 68
9.1.4 PEP Products Inc. and Interleukin Genetics Inc. Enter Collaborative Alliance 69
9.1.5 Pfizer Canada signs Alliance Deal with the Centre of Excellence For The Prevention of Organ Failure (Proof) 69
9.1.6 Millipore Corporation Acquires Guava Technologies 69
9.1.7 SuperGen Inc. Acquires Montigen Pharmaceuticals, Inc. 69
9.1.8 National Institute of Allergy and Infectious Diseases (NIAID) Enters Collaborative Alliance with Caprion Proteomics Inc. 69
9.1.9 Entelos Inc Acquires Iconix Biosciences 69
9.1.10 Vermillion Inc Acquires Ciphergen Biosystems 69
9.1.11 Cleveland Biolabs, Inc. Enters Collaborative Alliance with CBMS-MITS JPMO 69
9.2 Mergers and Acquisition Analysis by Deal Type 70
9.3 Mergers and Acquisition by Year of Consolidations 71
9.4 Mergers and Acquisitions by Geography 72
9.5 Mergers and Acquisitions by Deal value 72
10 Appendix 74
10.1 Abbreviations 74
10.2 Research Methodology 74
10.2.1 Coverage 75
10.2.2 Secondary Research 75
10.2.3 Primary Research 76
10.2.4 Expert Panel Validation 76
10.3 Contact Us 76
10.4 Disclaimer 76
1.1 List of Tables
Table 1: Biomarkers in Drug Discovery, Historical Revenue, Global Biomarkers Market,
($bn, 2000-2008) 33
Table 2: Biomarkers in Drug Discovery, Historical Revenue, Global Biomarkers Market,
($bn, 2008-2015) 34
Table 3: Biomarkers in Drug Discovery, Historical Revenue, Biomarker's Drug Discovery Market Revenue ($bn), 2000-2008 34
Table 4: Biomarkers in Drug Discovery, Historical Revenue, Global Biomarkers Drug Discovery Market Revenue ($bn), 2008-2015 34
Table 5: Biomarkers in Drug Discovery, Historical Revenues, Biomarker's Molecular Diagnostics Market Revenue ($bn), 2000-2008 35
Table 6: Biomarkers in Drug Discovery, Historical Revenue, Biomarkers Molecular Diagnostics Market Revenue ($bn), 2008-2015 35
Table 7: Biomarkers in Drug Discovery, Historical Revenue, Others Market Revenue ($bn), 2000-2008 36
Table 8: Biomarkers in Drug Discovery, Historical Revenue, Others Market Revenue ($bn), 2008-2015 36
Table 9: Biomarkers in Drug Discovery, Global, Regulatory Filings for Biomarkers, 2009 43
Table 10: Biomarkers in Drug Discovery, Global, Validated Biomarkers Applied in FDA Approved Drugs, 2009 44
Table 11: Biomarkers in Drug Discovery, Global,Biomarkers in Discovery Phase, 2009 62
Table 12: Biomarkers in Drug Discovery, Global, Biomarkers in Preclinical Phase, 2009 64
Table 13: Biomarkers in Drug Discovery, Global, Biomarkers in Phase I, 2009 65
Table 14: Biomarkers in Drug Discovery, Global, Biomarkers in Phase II, 2009 65
Table 15: Biomarkers in Drug Discovery, Global, Biomarkers in Phase III, 2009 65
Table 16: Biomarkers in Drug Discovery, Global, Merger and Acquisitions, 2009 68
1.2 List of Figures
Figure 1: Biomarkers in Drug Discovery, Global, History of Biomarkers, 2009 10
Figure 2: Biomarkers in Drug Discovery, Global, Biomarker Discovery and Validation Process, 2009 11
Figure 3: Biomarkers in Drug Discovery, Global, General Application of Biomarkers, 2010 12
Figure 4: Biomarkers in Drug Discovery, Global, Application of Biomarkers in Diagnosis, 2009 14
Figure 5: Biomarkers in Drug Discovery, Global, Potential Impact of Biomarkers on Disease States, 2009 15
Figure 6: Biomarkers in Drug Discovery, Global, Application of Biomarkers in Population Genetic Studies, 2009 16
Figure 7: Biomarkers in Drug Discovery, Global, Role of Biomarkers in Risk Assessment, 2009 17
Figure 8: Biomarkers in Drug Discovery, Global, Biomarkers Accelerate the Drug Discovery Process, 2009 19
Figure 9: Biomarkers in Drug Discovery, Global, Adoption of Biomarkers by Top Companies in Drug Discovery, 2009 21
Figure 10: Biomarkers in Drug Discovery, Global, Case Studies, 2009 23
Figure 11: Biomarkers in Drug Discovery, Global, Hepicidine Biomarker Case Study, 2009 24
Figure 12: Biomarkers in Drug Discovery, Global, Septin 9 Biomarker Case Study, 2009 26
Figure 13: Biomarkers in Drug Discovery, Global, PARP1 Gene Biomarker Case Study, 2009 30
Figure 14: Biomarkers in Drug Discovery, Global, Global Biomarkers Market Revenues ($bn), 2000-2015 33
Figure 15: Biomarkers in Drug Discovery, Global, Biomarker's Drug Discovery Market Revenues ($bn), 2000-2015 34
Figure 16: Biomarkers in Drug Discovery, Historical Revenue, Biomarkers Molecular Diagnostics Market Revenue ($bn), 2000-2008 35
Figure 17: Biomarkers in Drug Discovery, Global, Others Market Revenues ($bn), 2000-2015 36
Figure 18: Biomarkers in Drug Discovery, Global, Global Biomarkers Market Segmentation, 2009 37
Figure 19: Biomarkers in Drug Discovery, Global, Market Drivers and Restrains, 2009 37
Figure 20:Biomarkers in Drug Discovery, Global, Integration of 'Omics' Drive Global Biomarker Market, 2009 39
Figure 21: Biomarkers in Drug Discovery, Global, Biomarkers Fulfill Unmet Needs of Conventional Drug Discovery Methods, 2009 41
Figure 22: Biomarkers in Drug Discovery, Global, Validated Biomarkers Applied by Pharmaceutical Companies in Drug Discovery, 2009 45
Figure 23: Biomarkers in Drug Discovery, Global, Biomarkers Technology Adoption Framework, 2009 47
Figure 24: Biomarkers in Drug Discovery, Global, Company Profile - Quest Diagnostics, 2009 50
Figure 25: Biomarkers in Drug Discovery, Global, Company Profile - Applied Biosystems, 2009 51
Figure 26: Biomarkers in Drug Discovery, Global, Company Profile - Vermillion, 2009 52
Figure 27: Biomarkers in Drug Discovery, Global, Company Profile- BGMedical, 2009 53
Figure 28: Biomarkers in Drug Discovery, Global, Company Profile - Menarini, 2009 54
Figure 29: Biomarkers in Drug Discovery, Global, Company Profile- Abbott, 2009 55
Figure 30: Biomarkers in Drug Discovery, Global, Company Profile-Roche, 2009 56
Figure 31: Biomarkers in Drug Discovery, Global, Company Profile-Genentech, 2009 57
Figure 32: Biomarkers in Drug Discovery, Global, Company Profile- Affymetrix, 2009 58
Figure 33: Biomarkers in Drug Discovery, Global, Company Profile- Amgen, 2009 59
Figure 34: Biomarkers in Drug Discovery, Global, Geographic Landscape-Global Biomarkers Market, 2009 60
Figure 35: Biomarkers in Drug Discovery, Global, Pipeline Analysis by Phase, 2009 65
Figure 36: Biomarkers in Drug Discovery, Global, Pipeline Analysis by Therapeutic Class, 2009 66
Figure 37: Biomarkers in Drug Discovery, Global, Pipeline Analysis by Geography, 2009 67
Figure 38: Biomarkers in Drug Discovery, Global, Global Biomarkers Market – Deal Analysis, 2009 70
Figure 39: Biomarkers in Drug Discovery, Global, Mergers and Acquisition by Year of Consolidation, 2009 71
Figure 40: Biomarkers in Drug Discovery, Global, Mergers and Acquisitions – Geographical Distribution, 2009 72
Figure 41: Biomarkers in Drug Discovery, Global, Mergers and Acquisitions – Deal Value ($m), 2009 72
Figure 42: GBI Research Methodology 75
Companies Mentioned
Quest Diagnostics
Applied Biosystems
Vermillion
BGMedical
Menarini
Abbott
Roche
Genentech
Affymetrix
Amgen
To order this report:
Drug Discovery and Development Industry: Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626 (805)652-2626
Intl: +1 805-652-2626
Research and Markets: 2010 Plimsoll Analysis - Meat Wholesalers (Scotland) Analyses the UK's Leading 36 Companies and Rates Each on Their Acquisition Attractiveness
Buzz up! 0 Print..Press Release Source: Research and Markets Ltd. On Wednesday January 27, 2010, 10:04 am EST
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/e36449/2010_plimsoll_anal) has announced the addition of the "2010 Plimsoll Analysis - Meat Wholesalers (Scotland) - A comprehensive profile of 36 companies operating in the UK market" report to their offering.
The UK Meat Wholesalers (Scotland) market analysis
This edition of the Plimsoll Analysis is the most comprehensive review yet of the UK Meat Wholesalers (Scotland) industry. With the market due for a prolonged period of consolidation to weed out over capacity and weakened competitors, keeping up with development will be vitally important. Whether you are looking for companies to buy, thinking of selling or just keeping up with developments in the market, this special Plimsoll Industry Analysis will give you a new outlook on your market.
What you receive on each company
This special edition of our report is designed to alert you to merger and acquisition activity in your market. We individually assess each of the companies in their own 2 paged section of the report.
You will receive the following on each company:
•An individual valuation
•A full financial health assessment
•A breakdown of the board members and ownership structure
•A 10 point takeover attractive rating
Market Analysis
This section is packed with over 50 pages of market analysis.
•Market size - the latest year compared to the previous year
•Market share - which companies have increased sales far above the industry average?
•Sales growth - compare growth in the market over the last ten years
•Profitability analysis - which companies would be profitable but for the directors fees being taken out of the business? Discover how smaller companies compare to larger businesses.
•The top performing companies in your industry named, ranked and analysed in detail
Company Analysis
Each of the 36 companies in the Meat Wholesalers (Scotland) industry is clearly identified and analysed so at a glance you can assess their strengths and weaknesses.
•Each company is compared against the industry average so you can benchmark their performance over the last five years.
•Instantly assess which companies pose a threat to your business and those which could disappear from the market
Plenty of cash rich to rescue the needy
1 in 6 companies in the UK Meat Wholesalers (Scotland) industry could change ownership as a result of the current economic climate, claims a new study by leading financial analysts Plimsoll. With a surprising number of cash rich competitors waiting in the wings the market could be set for a prolonged period of consolidation. David Pattison, author of the new Plimsoll Industry Analysis - Meat Wholesalers (Scotland), explains, I am sure any director worth his salt would agree that, in the current climate, there are simply too many companies chasing too little market. With many directors eyeing the exit doors and highly leveraged buyouts consigned to history for the time being it really is a buyers market out there for cash rich companies. Pattison continues, In the Plimsoll Industry Analysis we have identified 0 companies that have a sizeable cash reserve sat on their balance sheets that, due to record low interest rates, is generating nothing. These companies are now in the position to buy up large chunks of market share at rock bottom prices and make that money work for them. They must be like kids in a sweet shop at the moment - all those distressed competitors available at a fraction of their true value.
The UK Meat Wholesalers (Scotland) market is still widely regarded as one of the UK's most fragmented sectors. In our report we analysed the UK's leading 36 companies are rated each on their acquisition attractiveness this will tell you which companies are set to be buying and which are exposed to takeover.
Key Topics Covered:
•Section 1: Best Trading Partners - the best in the industry
•Section 2: Sales & Market Performance
•Section 3: Profitability
Industry Analysis:
Each company in the industry analysed using the unique Plimsoll method. Every company is analysed, rated and valued over two pages, giving you a graphical appraisal of each company's financial performance in an instant.
Some of the Companies Mentioned:
•828 Catering Supply Ltd
•A P Jess (Paisley) Ltd
•A P Jess Ltd
•John Scott Meat (Paisley) Ltd
•Aberdeen Scotch Meat Ltd
•John Scott Meat (Paisley) Ltd
•Argyll Bakeries Ltd
•Macfarlane Meat Products Ltd
•Binn Farm Ltd
•Mathers (Inverurie) Ltd
•Brown Brothers (Manufacturing) Ltd
•Nimmo (Holdings) Ltd
•Bryson Meats Ltd
•Orkney Meat Ltd
•Buccleuch Heritage Brands Ltd
•Orkney Meat Ltd
•Easdale Seafoods Ltd
•P R Duff Ltd
•Forth Meat Supplies Ltd
•Reston Auction Mart Ltd
•Freddie Phillips Meat Importers Ltd
•Robert Watson Fruit (Glasgow) Ltd
•Freshcut (Aberdeen) Ltd
•Scottish Association Of Meat Wholesalers
•George Campbell & Sons (Fishmongers) Ltd
•Strachans Ltd
•J & A Cumming Ltd
•Tarelgin Farm Foods Ltd
•J F Finlay & Co Ltd
•Vivers Ltd
For more information visit http://www.researchandmarkets.com/research/e36449/2010_plimsoll_anal
Contact:
Research and MarketsLaura Wood, Senior ManagerU.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716 +353-1-481-1716press@researchandmarkets.com
Response Mine Interactive Reveals the Six Biggest Mistakes Marketers Make in Customer Acquisition Marketing
New White Paper Outlines Why Lead Generation Fails Most Marketers
Buzz up! 0 Print..Press Release Source: Response Mine Interactive On Wednesday January 27, 2010, 10:00 am EST
ATLANTA, Jan. 27 /PRNewswire/ -- Advanced marketers share six mistakes in their approach to converting online leads, according to a new white paper from the customer acquisition marketing experts at Response Mine Interactive (RMI).
The digital agency's recently released white paper, "Why Lead Generation Fails: The Six Mistakes Advanced Marketers Make that Kill Customer Acquisition Marketing," reveals the frequent errors marketers make in customer acquisition marketing and outlines the proven lead generation strategies to create powerful customer acquisition channels. These six mistakes include:
1.Falling into the 'cost per lead' trap
2.Wasting traffic with poor conversion
3.Failing to use content to pre-qualify the person
4.Forcing the form
5.Stopping after becoming number one
6.Failing to invest in testing
The white paper also highlights a real-world client case study to demonstrate effective lead generation techniques and business results.
"In pay-per-performance campaigns, many marketers end up paying for leads that don't convert," commented Ken Robbins, president and founder of RMI. "With our experience and expertise in customer acquisition marketing, RMI gives sophisticated marketers the necessary insight to increase conversion rates and create a successful program that gives you not just leads but the customers you're paying for."
RMI's customer acquisition marketing white paper is now available to download for free at leadgenfails.responsemine.com.
About Response Mine Interactive
Response Mine Interactive (RMI) uses advanced direct response marketing strategy and interactive media optimization to help clients expand their customer acquisition marketing. Founded in 2001, RMI serves leading brands in the travel, health care, home services and retail sectors. Located in Atlanta, Ga., RMI delivers breakthroughs in volume and efficiency built around a unique strategy of margin-based decision making and a culture of testing. RMI's ultimate mission is to acquire more customers for its clients. For more information, visit www.responsemine.com or call 404-233-0370
L2 .35 x .38 20K vol
FRMC .35 x .38 20K vol
Takeover risk for major NY AIDS and trauma center
Major NY AIDS and trauma center at risk of takeover, conversion to community health center
Buzz up! 0 Print..By Verena Dobnik, Associated Press Writer , On Wednesday January 27, 2010, 11:22 am
NEW YORK (AP) -- St. Vincent's Hospital, a major AIDS and trauma center, could be taken over by a powerful nonprofit New York hospital system and stripped of its surgical and inpatient units if its finances don't improve.
However, "if St. Vincent is able to continue to meet its mission on its own, they have our full support," Continuum Health Partners said in a statement Tuesday.
If Continuum's proposal to take control of the cash-strapped Greenwich Village institution goes through, St. Vincent's would become a community health center with ambulatory care, forfeiting surgical services and inpatient beds within about three months.
That would leave Lower Manhattan's west side without a full-service hospital.
"St. Vincent's is an outpost of health care on the West Side," said state Sen. Tom Duane, D-NY, who represents the area. "You can't control what kind of emergency treatment people need. Remember what happened on 9/11?"
The 727-bed hospital, founded 160 years ago, was the closest hospital to the World Trade Center after the 9/11 terror attack.
The other nearest medical facilities are on Manhattan's East Side, including the New York Downtown Hospital, the Beth Israel Medical Center and the Bellevue Hospital Center. Roosevelt Hospital is almost 40 blocks uptown, at West 58th Street.
Continuum already operates Beth Israel, St. Luke's and Roosevelt hospitals.
But a takeover is far from a done deal.
The proposal to St. Vincent's board was "submitted at its request" and "intended as an alternative to financial liquidation," Continuum said in its statement.
St. Vincent's is hundreds of millions of dollars in debt, and has defaulted on its Chapter 11 reorganization plan after missing a payment to a trust fund linked to medical malpractice cases.
Henry J. Amoroso, chief executive of St. Vincent Catholic Medical Centers, blames his institution's failing finances on a series of state budget cuts in the past two years as well as the recession.
In a statement Tuesday, Amoroso said he believes the facility will work with its lenders, GE Capital and TD Bank, and "emerge as a stronger healthcare system" for the hundreds of thousands of patients treated there each year.
The Nation's Three Leading Independent Voting Advisory Firms Recommend Shareholders Approve Xerox Acquisition of ACS
Buzz up! 0 Print..Companies:Affiliated Computer Services, Inc.Xerox Corp..Related Quotes
Symbol Price Change
ACS 61.78 -0.33
{"s" : "acs,xrx","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Xerox Corporation On Wednesday January 27, 2010, 11:18 am
NORWALK, Conn.--(BUSINESS WIRE)--The nation's three leading independent voting advisory firms have recommended shareholders vote "FOR" Xerox Corporation’s (NYSE: XRX - News) acquisition of Affiliated Computer Services, Inc. (NYSE: ACS - News). RiskMetrics Group, Glass Lewis & Co., and PROXY Governance, Inc. each have published analyses recommending that ACS and Xerox shareholders support the transaction.
In its analysis published Jan. 25, RiskMetrics said, “The consensus view of shareholders appears to portray confidence in Xerox management’s ability to successfully integrate ACS.”
“The merger is expected to create a global enterprise that can enhance the combination of products and support services for its customers,” said Glass Lewis in recommending that Xerox shareholders approve the acquisition.
PROXY Governance noted strong support from equity analysts on both the valuation and strategic vision of the acquisition, and stated in its report, “We believe shareholders will be best served by supporting the proposed transaction.”
Special meetings of shareholders will be held on Feb. 5 for Xerox and ACS shareholders to vote on the acquisition, which will transform Xerox into the world’s leading enterprise for business process and document management.
About Xerox
Headquartered in Norwalk, Conn., Xerox Corporation's 54,000 people represent the world's leading document management, technology and services enterprise, providing the industry's broadest portfolio of color and black-and-white document processing systems and related supplies, as well as document management consulting and outsourcing services.
About Affiliated Computer Services
Headquartered in Dallas, ACS' 76,000 professionals support thousands of multinational corporations and government agencies in more than 100 countries from 500 locations. It offers business process and information technology outsourcing services in areas that include finance services, communications, transportation, human resources, healthcare, transaction processing, and customer care.
Note: For more information on Xerox, visit http://www.xerox.com or http://www.xerox.com/news. For open commentary, industry perspectives and views from events visit http://twitter.com/xeroxcorp, http://twitter.com/xeroxevents, http://www.xerox.com/blogs or http://www.xerox.com/podcasts.
Xerox® and the sphere of connectivity design are trademarks of Xerox Corporation in the United States and/or other countries.
This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "will," "should" and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements reflect management's current beliefs, assumptions and expectations and are subject to a number of factors that may cause actual results to differ materially. These factors include but are not limited to the unprecedented volatility in the global economy; the risk that unexpected costs will be incurred; the outcome of litigation and regulatory proceedings to which we may be a party; actions of competitors; changes and developments affecting our industry; quarterly or cyclical variations in financial results; development of new products and services; interest rates and cost of borrowing; our ability to protect our intellectual property rights; our ability to maintain and improve cost efficiency of operations, including savings from restructuring actions; changes in foreign currency exchange rates; changes in economic conditions, political conditions, trade protection measures, licensing requirements and tax matters in the foreign countries in which we do business; reliance on third parties for manufacturing of products and provision of services; the risk that we will not realize all of the anticipated benefits from the acquisition of Affiliated Computer Services, Inc.; and other factors that are set forth in the "Risk Factors" section, the "Legal Proceedings" section, the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section and other sections of our 2008 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009, June 30, 2009 and September 30, 2009 and ACS's 2009 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 filed with the Securities and Exchange Commission. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.
The proposed merger transaction involving Xerox and ACS will be submitted to the respective stockholders of Xerox and ACS for their consideration. In connection with the proposed merger, Xerox filed with the SEC, and the SEC declared effective on December 23, 2009, a registration statement on Form S-4 that included a joint proxy statement of Xerox and ACS that also constitutes a prospectus of Xerox and each of the companies may be filing with the SEC other documents regarding the proposed transaction. Xerox will mail the joint proxy statement/prospectus to its stockholders. Xerox and ACS urge investors and security holders to read the joint proxy statement/prospectus regarding the proposed transaction before making any voting or investment decision because it contains important information. You may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about Xerox and ACS, without charge, at the SEC's Internet site (http://www.sec.gov). Copies of the joint proxy statement/prospectus and the filings with the SEC that will be incorporated by reference in the joint proxy statement/prospectus can also be obtained, without charge, from Xerox's website, http://www.xerox.com, under the heading "Investor Relations" and then under the heading "SEC Filings". You may also obtain these documents, without charge, from ACS's website, http://www.acs-inc.com, under the tab "Investor Relations" and then under the heading "SEC Filings".
Xerox, ACS and their respective directors, executive officers and certain other members of management and employees may be deemed to be participants in the solicitation of proxies from the respective stockholders of Xerox and ACS in favor of the merger. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the respective stockholders of Xerox and ACS in connection with the proposed merger are set forth in the joint proxy statement/prospectus filed with the SEC. You can find information about Xerox's executive officers and directors in its definitive proxy statement filed with the SEC on April 6, 2009. You can find information about ACS's executive officers and directors in its annual report on Form 10-K filed with the SEC on August 27, 2009. You can obtain free copies of these documents from Xerox and ACS websites using the contact information above.
Contact:
Xerox CorporationCarl Langsenkamp, +1-585-423-5782 +1-585-423-5782carl.langsenkamp@xerox.com
Oracle completes acquisition of Sun Microsystems
Oracle completes purchase of Sun Microsystems, a week after European regulators give approval
Buzz up! 0 Print..Companies:Oracle Corp..By The Associated Press , On Wednesday January 27, 2010, 10:36 am EST
Oracle says its $7.4 billion purchase of Sun Microsystems has been completed.
The closing of the all-cash deal comes one week after the European Union gave its long-awaited approval, saying the combined company will not significantly affect competition in its markets.
Business software developer Oracle said it was buying Sun, a struggling computer server and software maker, last April. The U.S. Department Justice cleared the acquisition four months later.
The deal gives Oracle ownership of the Java programming language, which runs on more than a billion devices, and the Solaris operating system.
Sun, was a dot-com highflyer that advanced technology used to link computers together, making them more useful.
Northern Empire Acquires the Waskatenau Prospect
Buzz up! 0 Print..Press Release Source: Northern Empire Energy Corp. On Wednesday January 27, 2010, 10:00 am EST
CALGARY, Alberta, Jan. 27 /PRNewswire-FirstCall/ -- Northern Empire Energy Corp. ("the Company"; OTC Bulletin Board: NOEE) is pleased to announce it has acquired 100% of the Petroleum and Natural Gas lease rights on nine sections in the Redwater Region, north-east of Edmonton Alberta, Canada.
The Waskatenau Prospect consists of 9 sections (5760 acres) located 15 miles North East of the giant Redwater Oil Field. Several (12) Geophysical targets have been identified throughout the Waskatenau Prospect, the Company's 2010 Exploration Program plans to define and prioritize these targets.
The Redwater Atoll Reef is classified as one of the major petroleum fields in the world, of Leduc age and a prolific oil reservoir. In excess of 700 million barrels of oil have been produced from the Redwater oil field to date.
Separately, after completing a detailed geological, geophysical and seismic review, including current project economics, the Company has decided it is not in its best interests to proceed with its option to earn a 45% interest in the Turin Prospect.
Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The company's actual results could differ materially from those anticipated in the forward-looking statements. There is an inherent risk in an oil and gas exploration, and management can offer no assurances that "any" exploration program will be successful.
lol... nice
Management Team, Advisors & Consultants
http://www.formcapcorp.com/index.php?option=com_content&view=article&id=46&Itemid=60
FRMC Management Team, Advisors & Consultants
http://www.formcapcorp.com/index.php?option=com_content&view=article&id=46&Itemid=60
CRXX having getting some luv today
New home sales fall 7.6 pct in December
Sales of new homes sink 7.6 percent in December as industry wraps up weakest year on record
Buzz up! 0 Print..Companies:Beazer Homes Usa Inc.Dr Horton Inc.Hovnanian Enterprises Inc..Related Quotes
Symbol Price Change
BZH 4.08 0.00
DHI 11.48 +0.19
HOV 3.55 -0.03
KBH 14.82 +0.23
LEN 14.67 +0.11
{"s" : "bzh,dhi,hov,kbh,len,mdc,mho,mth,nvr,phm,ryl,tol","k" : "c10,l10,p20,t10","o" : "","j" : ""} By Alan Zibel, AP Real Estate Writer , On Wednesday January 27, 2010, 11:18 am
WASHINGTON (AP) -- New home sales unexpectedly fell 7.6 percent last month, capping the industry's weakest year on record.
The Commerce Department said December sales fell to a seasonally adjusted annual rate of 342,000 from an upwardly revised November pace of 370,000. Economists surveyed by Thomson Reuters had forecast a pace of 370,000 for December.
The results were the weakest since March and indicated demand remains sluggish despite newly expanded tax incentives to spur sales. The report is likely to fuel concern that the housing market turnaround will falter when government support ends this spring.
Housing remains one of the weakest links for the economic recovery, and is weighing on the minds of Federal Reserve officials who will issue a policy statement Tuesday afternoon at the end of a two-day meeting.
No major changes in interest rates are expected. The big question is whether Fed will revise its strategy to keep mortgage rates low. The Fed has been buying $1.25 trillion in mortgage-backed securities, but has said it will phase out the program by the end of March.
Only 374,000 homes were sold last year, down 23 percent from a year earlier and the weakest year on records dating back to 1963. December's sales were nearly 9 percent below the same month last year. This year, the National Association of Homebuilders is forecasting more than 500,000 sales.
Even if that happens, "it hardly makes you ecstatic," said Bernard Markstein, senior economist at the trade group, noting that the industry clocked more than 1 million sales a year from 2003 through 2006
Home sales have had a rocky recovery from their four-year slide. December's sales pace for new homes was up 4 percent from the bottom in January 2009, but down 75 percent from the peak in July 2005.
The median sales price of $221,300 in December was down nearly 4 percent from $229,600 a year earlier, but up about 5 percent from November's median of $210,300.
New home sales varied widely across the country. Sales of new homes plummeted by 41 percent in the Midwest and fell by 7 percent in the south. But they skyrocketed 43 percent in the Northeast and rose 5 percent in the West.
"You have some builders that are still struggling while others are doing well," said Brad Hunter, chief economist with Brad Hunter, chief economist with Metrostudy, a real estate research and consulting firm.
Any housing recovery this year is likely to be slow and labored. Experts forecast sales of new and previously occupied homes to weaken after tax credits for homebuyers expire in April.
So far, the housing recovery has been fueled mainly by hundreds of billions in federal spending that has pushed down mortgage rates and propped up demand. Congress decided last year to extend a tax credit of up to $8,000 for first-time buyers until the end of April. Homeowners who have lived in their current properties for at least five years can claim a tax credit of up to $6,500 if they relocate.
There were 231,000 new homes for sale at the end of December, down about 2 percent from November and the lowest inventory level since April 1971. But at the current lackluster sales pace, that still represents 8 months of supply -- above a healthy level of around 6 or 7 months.
John Freer, president of Riverworks Inc., a custom home builder in Missoula, Mont. who builds environmentally sustainable homes, said traffic and sales have been picking up. Along with the tax credit, he said, "I think people are a little bit more optimistic than they were last year."
AP Real Estate Writer Alex Veiga contributed to this report.
Backroom health care deals fuel voter anger
Outrage over health care deals undercut Obama's signature issue
Buzz up! 0 Print..By Charles Babington, Associated Press Writer , On Wednesday January 27, 2010, 11:25 am
WASHINGTON (AP) -- Special legislative favors, especially one designed to secure a Nebraska senator's vote for the embattled health care package, ignited so much public outrage that President Barack Obama is calling them a mistake and House leaders say the bill can't be resurrected unless such sweetheart deals are scrapped.
Obama says Americans were understandably upset by the backroom dealmaking that he called ugly. In a cruel twist, the reaction helped elect a Republican senator in Massachusetts last week, putting the health legislation in peril.
Some Senate Democrats urged party leaders to put health care on a back burner. Rep. Jim Clyburn of South Carolina, the No. 3 House Democrat, said Tuesday the House may be able to pass the Senate-approved version of the bill -- and salvage Obama's top domestic priority -- if the offending items are deleted.
"We've got to get rid of that Nebraska stuff, we've got to get rid of the Louisiana stuff," Clyburn said, referring to provisions inserted to help secure the votes of holdout Democratic senators Ben Nelson of Nebraska and Mary Landrieu of Louisiana.
Obama, speaking to ABC News this week, said, "I didn't make a bunch of deals." But he acknowledged making "a legitimate mistake" by letting White House and congressional negotiators include the items during last month's closed-door negotiations.
Most ire has focused on the Nebraska provision, even though it resembled countless other favors that have secured lawmakers' votes for decades. Republicans caught Democrats flatfooted by turning derision of the "Cornhusker Kickback" into a national furor.
Strategists say Democratic leaders underestimated their foes' ability to use the Internet and other outlets to feed unsavory depictions of legislative dealmaking to angry voters already suspicious of Congress.
"The political dynamics have changed," said Democratic consultant Chris Kofinis. "The Google electorate," he said, can swap political information and opinions with lightning speed. Average Americans may know little about congressional traditions for brokering deals, he said, but when they hear about it, "they don't have a lot of patience for the sausage-making process."
Obama basically conceded the point this week, after reaction to the Nebraska item helped Republican Scott Brown win a stunning victory to succeed the late Sen. Edward Kennedy in Massachusetts. Brown's election jeopardized the health care overhaul that Kennedy long championed by taking away the 60-vote Democratic supermajority and the Democrats' ability to cut off GOP filibusters.
"It's an ugly process and it looks like there are a bunch of backroom deals," Obama told ABC News. In Wednesday night's State of the Union address, he said, he will "own up to the fact that the process didn't run the way I ideally would like it to and that we have to move forward in a way that recaptures that sense of opening things up more."
He said he has kept "the promises we made about increased transparency" at the White House, even though he once had advocated televising health care negotiations on C-SPAN.
Nelson, who defended his actions in a Senate speech Monday, was upset last year that Nebraska would have to pay for a proposed expansion of Medicaid starting in 2017. He says he argued that the federal government should cover the full cost for all 50 states, not just Nebraska.
But such an agreement would have cost about $35 billion over 10 years. So White House and Senate Democratic negotiators agreed to apply the break only to Nebraska, at a cost of about $100 million, Senate officials said.
As soon as GOP operatives spotted the change, they dubbed it the "Cornhusker Kickback," and denounced it as a blatant payoff for Nelson's vote. Democratic leaders, knowing that both parties have often used such tactics to placate holdout lawmakers, seemed slow to react.
The most immediate impact was in Massachusetts, where Brown was running an under-the-radar campaign against heavily favored Democrat Martha Coakley. With conservative talk shows and bloggers fueling the fire, Democrats belatedly realized that Brown was surging.
"That Nebraska thing is really hurting us," former President Bill Clinton told House Democrats a few days before the Jan. 19 Massachusetts special election.
In a final-hour campaign speech, Brown denounced "those backroom deals for Nebraska and others."
A post-election poll by The Washington Post, the Kaiser Family Foundation and Harvard University found that Brown hit a nerve, even though Massachusetts voters had mixed feelings about health care in general. Nearly half said they opposed Obama's health initiatives. But 68 percent said they favored their own state's universal health care plan, which Massachusetts enacted several years ago -- with Brown's vote.
Worcester teacher Kathleen Halloran, 47, told The Associated Press that a national health care revision "really needs to be a collaborative effort at real, true reform, not some political agenda, not these backroom deals where Nebraska gets exempt."
Nelson says he feels unfairly targeted by taunts of a "Cornhusker Kickback," when all he wanted was to stop Congress from imposing more unfunded mandates on the states. He said he was slow to realize the firestorm's impact because he was more focused on other matters, such as blocking a publicly run health insurance program.
Asked about the condemnation of the Nebraska deal, Senate Majority Leader Harry Reid, D-Nev., said Tuesday, "All senators, Democrats and Republicans, work hard to represent the states and the needs of their states."
Associated Press writer Steve LeBlanc in Boston contributed to this report.
NERA Economic Consulting Releases Canadian Securities Class Action Trends Report
Filings Remain High; Settlement Values Fall
Buzz up! 0 Print..Press Release Source: NERA Economic Consulting On Wednesday January 27, 2010, 11:21 am
TORONTO--(BUSINESS WIRE)--Securities class action filings in Canada for 2009 remained above historical average filings, according to Trends in Canadian Securities Class Actions: 2009 Update, released today by NERA Economic Consulting.
Eight securities class actions were filed in 2009, compared with the 10 filings in 2008. While filings are lower this year, they are still higher than any other year since class action legislation was first enacted in Canada.
Settlement values for securities class actions in 2009 were significantly lower than in 2008, with six cases settled in 2009 for approximately $51 million in total payments versus eight cases for approximately $890 million in total payments in 2008. The average settlement for 2009 was $8.5 million and the median settlement was $9 million.
“While securities class action litigation is still in its infancy in Canada, the maturation of this type of litigation continued during 2009,” said Mark Berenblut, NERA Senior Vice President and Trends co-author. “Most notable this year, because of their potential impact on future trends in Canadian securities class actions, are the decisions of the Ontario Superior Court of Justice certifying three securities class actions, and the decision in IMAX granting leave for the plaintiffs to pursue claims under Part XXIII.1 of the Ontario Securities Act – the first such ruling on an application to proceed with claims under the new secondary market liability provisions of the provincial Securities Acts.”
Trends
Additional key findings from the report are:
•There are now more than $14.7 billion in outstanding plaintiffs’ claims in Canadian securities class actions.
•A record six new cases were filed in 2009 involving allegations of misrepresentations and/or omissions by issuers, including claims brought under the new continuous disclosure provisions.
•Notably in 2009, there is a complete absence of new securities class actions filings related to the credit crisis. The authors believe the lack of this type of filings is likely a reflection of the relatively smaller impact of the credit crisis on the Canadian financial system as compared to that in the United States. In the US, 2009 witnessed more than 60 new filings related to the credit crisis.
•The majority of 2009 filings were brought in relation to securities issued by companies in the minerals and financial sectors—two cases against gold mining companies, one against a coal mining company, and three cases against issuers in the financial sector.
Outlook
Looking forward to 2010, the authors note that the pace of new filings may depend on many factors, possibly including any additional rulings from the courts (including any appellate decisions), the pace and extent of the economic recovery, and any changes in corporate governance practices of Canadian issuers in light of the perception of a growing threat of significant litigation.
Securities Class Action Trends Report Series
NERA has been analyzing trends in securities class actions for more than 15 years. In addition to this Canada Trends report, the firm produces two US Trends studies annually, and produced a Japan Trends report in 2009.
Mark Berenblut and Bradley Heys, co-authors of Trends in Canadian Securities Class Actions: 2009 Update, are available to discuss their findings with the press. To read the full report, visit: http://www.nera.com/publication.asp?p_ID=4039.
About NERA
NERA Economic Consulting (www.nera.com) is a global firm of experts dedicated to applying economic, finance, and quantitative principles to complex business and legal challenges. For nearly half a century, NERA's economists have been creating strategies, studies, reports, expert testimony, and policy recommendations for government authorities and the world's leading law firms and corporations. We bring academic rigor, objectivity, and real world industry experience to bear on issues arising from competition, regulation, public policy, strategy, finance, and litigation.
NERA's clients value our ability to apply and communicate state-of-the-art approaches clearly and convincingly, our commitment to deliver unbiased findings, and our reputation for quality and independence. Our clients rely on the integrity and skills of our unparalleled team of economists and other experts backed by the resources and reliability of one of the world's largest economic consultancies. With its main office in New York City, NERA serves clients from over 20 offices across North America, Europe, and Asia Pacific.
Contact:
NERA Economic ConsultingBenjamin Seggerson, +1 202-466-9232 +1 202-466-9232Public Relations Managerben.seggerson@nera.com
GOP says Ohio governor is taking too much credit
GOP challenger says Ohio's Democratic governor does too little, takes credit for too much
Buzz up! 0 Print..Companies:Procter Gamble Co..
AP - Ohio Gov. Ted Strickland delivers the State of the State address to a joint session of the Ohio ...
Related Quotes
Symbol Price Change
PG 60.19 -0.50
{"s" : "pg","k" : "c10,l10,p20,t10","o" : "","j" : ""} By Julie Carr Smyth, AP Statehouse Correspondent , On Wednesday January 27, 2010, 11:20 am
COLUMBUS, Ohio (AP) -- The content of Ohio Gov. Ted Strickland's State of the State speech has quickly become fodder for the upcoming election fight.
Republican John Kasich, challenging Strickland's fall re-election bid, after hours Tuesday recorded and distributed a video message that criticized the Democratic governor for doing too little and taking credit for too much.
"While he tried to paint Ohio in the best possible light, a large part of public service is not what you promise for the future, it's what you did when your hands were on the wheel," Kasich said.
Strickland, in the last State of the State address of his four-year term, gushed affection and respect for his ailing state and pledged to "move heaven and earth to create jobs" with a modest battery of new initiatives that cost little money.
Acknowledging that "yes, we have been knocked down," Strickland said "the state of the state is unyielding" amid the economic downturn, which has led to a 10.9 percent unemployment rate and shown little sign of recovery.
"Ohio will rise again," he vowed Tuesday before the packed House chamber. "Because there isn't a single thing wrong with Ohio that can't be fixed by what's right with Ohio."
Strickland, who's dealing with falling approval ratings as he fights for re-election in November, promised things would improve thanks to the state's history of invention and innovation.
"I believe in Ohio because we will invest in the things we do exceptionally well," Strickland said. "And we will create jobs."
New spending programs are typically a hallmark of a governor's annual address to lawmakers, but Strickland has been hobbled by lagging state revenues and a promise not to raise taxes. The best he could do was a $40 million investment in green energy technologies funded largely with federal dollars.
He wants the state to pursue a biorefinery that converts food grown in Ohio into biopolymers used in products such as toothbrushes and cell phones.
"There will come a day when Ohio will be the undisputed home of advanced energy," Strickland said. "A day when we cast off those two tired words that have been used to put us down: Rust Belt. Because that's not who we are."
Other efforts he advanced require few additional resources. They include creating a business lending gateway to link businesses seeking working capital with bankers willing to lend, reducing taxes on new solar and wind energy generation, designating Ohio's eight largest urban areas as hub cities in their strongest industries and reducing red tape for companies doing business in the state.
The governor also announced a new partnership between Ohio's public universities and consumer products manufacturer Procter & Gamble Co. to help university researchers bring products to market faster. And he proposed a plan to improve access to state-grown food to boost rural jobs and make more healthy food available.
Republican lawmakers said many of the positive developments Strickland claimed in his speech began with their ideas. That included the Third Frontier high-tech initiative, started under his Republican predecessor, Bob Taft, and tougher standards for public education.
"It sounds like what the governor has done is rename programs and rehash them," said state Rep. Lou Blessing, R-Cincinnati.
Democratic House Speaker Armond Budish said he thought Strickland's speech helped the governor's re-election effort.
"I believe the more the governor communicates about what he has done, and the more we communicate about what we have done, the public will respond," Budish said. "The governor has a lot of great accomplishments to talk about."
Brian Rothenberg, executive director of the liberal group ProgressOhio.com, suggested the upcoming election had an impact on reaction to Tuesday's speech.
"Three years ago, the very same speech would have been met with bipartisan applause," he said. "But it's election year, and the toxic quest for power has changed Ohio's Statehouse."
Associated Press writers Matt Leingang and Andrew Welsh-Huggins contributed to this report.
Wis. gov defends record on taxes, focuses on jobs
Wis. gov defends his record on taxes, focuses on job creation in final State of State speech
Buzz up! 0 Print..
AP - Gov. Jim Doyle addresses a joint session of the Legislature in the Assembly chambers at the State Capitol ...
By Scott Bauer, Associated Press Writer , On Wednesday January 27, 2010, 11:18 am
MADISON, Wis. (AP) -- Wisconsin Gov. Jim Doyle, in his final year as governor, used his last State of the State speech Tuesday to talk about sending people back to work and to defend his record on taxes.
In a speech before a joint meeting of the Legislature, Doyle argued that he protected the middle class from tax increases during a time when the state faced record-high budget shortfalls and unemployment levels not seen for decades.
Republicans called him a hypocrite who was trying to make people forget about billions in tax increases he approved, including more than $2 billion in the current budget.
"I think it was Jim Doyle's last work of fiction," said Assembly Minority Leader Rep. Jeff Fitzgerald, R-Horican. "I think the governor has tried to reinvent himself."
Doyle touted tax incentives enacted last year, which he said have kept companies such as Mercury Marine in the state and attracted others to relocate.
"I have a year left as governor, and I want to be very clear about what my top priority will be," Doyle said. "I will do everything I can to help our businesses create jobs and give our workers the opportunities to get those jobs. Nothing is more important."
Doyle also urged lawmakers to pass a host of new tax incentives for the agriculture and dairy industries, among others, and increase funding for business investments. He also called for passing legislation that could help remove obstacles for a commuter-rail service linking Milwaukee, Kenosha and Racine. He called it a "jobs bill."
Determined to avoid being dismissed as a lame duck, Doyle also emphasized unfinished business he said the Legislature should deal with before their session ends in three months.
That includes a divisive proposal to cede control of Milwaukee schools to the mayor and a sweeping climate change bill that would impose a variety of new mandates, including requiring that 25 percent of the state's energy come from renewable sources by 2025.
Both proposals face stiff opposition.
Doyle argued that his climate change proposal would help kick-start the economy and create thousands of new jobs.
"Clean energy technology and high-end manufacturing are Wisconsin's future," Doyle said. "This is not some pie in the sky. Anyone who says there aren't jobs in the clean energy economy had better open their eyes."
There's no doubt the state's economy continues to struggle.
Wisconsin's seasonally adjusted unemployment rate was 8.7 percent in December, up 2.8 percent from when Doyle delivered his State of the State in 2009. About 163,000 people have lost their jobs since then.
Senate Minority Leader Sen. Scott Fitzgerald, R-Juneau, called Doyle a hypocrite for talking about job creation at a time when so many have been lost.
Doyle defended his record on taxes, saying that during his seven years as governor Wisconsin has dropped from the fourth-highest taxed state in the country to 15th.
"We've protected our priorities while also protecting the middle class from tax increases," he said.
Last year Doyle approved more than $2.1 billion in tax increases, but there were no general sales tax hikes or income tax increases for anyone earning less than $300,000. The budget also included more than $2.2 billion in federal stimulus money.
Even with those tax increases, the budget is on shaky ground. Doyle said more cuts were necessary but he didn't elaborate other than to say priorities would be protected.
Doyle announced a new $100 million revolving loan fund for manufacturers to reduce their energy costs, using existing state and federal money.
He also called for a constitutional amendment to allow for property tax relief to be sent directly to homeowners. That is not allowed now.
In addition to using his final State of the State to talk about what he wants to get done over the next 11 months, Doyle briefly used it as a chance to look back. Doyle, a Democrat, is wrapping up his second term and decided against seeking a third.
He touted the expansion of health care programs in the state during his tenure. The growth in BadgerCare programs put Wisconsin in position to have 98 percent of all residents covered by health insurance.
Doyle is proposing a new basic coverage plan for about 21,000 childless adults who are currently on a waiting list for a more expansive plan. The plan is designed to pay for itself through premiums paid by those enrolled.
One of the main candidates vying to replace Doyle next year, Republican Scott Walker, gave his own speech in the Capitol Rotunda just three hours before Doyle. Walker, the current Milwaukee County Executive, dubbed his speech the "State of the Economy" and was surrounded by Republican state lawmakers. Saying the state of Wisconsin's economy is "weak," Walker called on Democrats who control the Legislature to repeal business tax increases and block Doyle's climate change proposal.
Walker's biggest Republican challenger is former U.S. Rep. Mark Neumann. He was not campaigning Tuesday.
The main Democratic candidate, Milwaukee Mayor Tom Barrett, spent the hours before Doyle's speech hosting a fundraiser where suggested donations ranged from $50 to $2,500.
Pierce Enters China Market with Sale of Six Pumpers to Jiangsu Province Fire Bureau
Buzz up! 0 Print..Companies:Oshkosh Corporation.Related Quotes
Symbol Price Change
OSK 34.63 -0.53
{"s" : "osk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Oshkosh Corporation On Wednesday January 27, 2010, 11:14 am
OSHKOSH, Wis.--(BUSINESS WIRE)--Oshkosh Corporation (NYSE: OSK - News), announced today that its subsidiary, Pierce Manufacturing, reported its first ever sale of Pierce fire apparatus in China. A new order for six Pierce® custom pumpers was received from the Nanjing, Jiangsu Province Fire Bureau in the People’s Republic of China. The vehicles are scheduled for delivery in June 2010.
“Pierce is honored to have been selected by the Jiangsu Province Fire Bureau for this municipal fire truck order. We are proud to provide this new customer with the most technologically-advanced and best performing fire trucks in the world,” said Wilson Jones, Oshkosh Corporation executive vice president and president, Fire & Emergency. “The sale reflects Oshkosh Corporation’s dedication to increasing international sales through outstanding customer support and after sales service.”
The contract will provide Jiangsu Province with advanced fire protection along with technical services and parts. The six Pierce pumpers, built on Saber® chassis, are customized to meet the unique needs of the Jiangsu Province Fire Department and also to meet the China Compulsory Certification (CCC) standards concerning product safety. Jiangsu Province is located 300km west of Shanghai, has a population of 73 million and its gross domestic product is amongst the strongest in China. The region aspires to be the high-technology corridor of China and most of the largest global companies have a presence there. Urbanization in Jiangsu Province is second only to that in the city of Shanghai.
“Oshkosh first made inroads to China by selling our Airport Rescue & Fire Fighting equipment. We were able to build upon those relationships to introduce the region to the Pierce fire apparatus and the features that these specialized departments need,” said Desmond Soh, Oshkosh Corporation president Asian Operations. “This is a milestone for both the customer and the company, and we will continue to leverage the relationships.”
Each Pierce pumper is equipped with a 1500 gallons per minute (gpm) midship pump, Husky® 12 foam system and a 200 cfm (95 lps) compressed air foam system(CAFS) for enhanced firefighting power. Other features include a 10-inch raised roof cab for easier ingress and egress and large storage compartments with roll-up doors. In addition, the vehicles are engineered with a removable passenger side pump panel to allow easier access for maintenance.
About Pierce Manufacturing
Pierce Manufacturing Inc., an Oshkosh Corporation [NYSE: OSK] company, is the leading North American manufacturer of custom fire apparatus. Products include custom and commercial pumpers, aerials, rescue trucks, wildland trucks, minipumpers, elliptical tankers, and homeland security apparatus. In addition, Pierce designs its own foam systems and was the first company to introduce frontal airbags and the Side Roll Protection system to fire apparatus. To learn more about Pierce visit www.piercemfg.com.
About Oshkosh Corporation
Oshkosh Corporation is a leading designer, manufacturer and marketer of a broad range of specialty access equipment, commercial, fire & emergency and military vehicles and vehicle bodies. Oshkosh Corporation manufactures, distributes and services products under the brands of Oshkosh®, JLG®, Pierce®, McNeilus®, Medtec®, Jerr-Dan®, Oshkosh Specialty Vehicles, Frontline™, SMIT™, CON-E-CO®, London® and IMT®. The Oshkosh brands are valued worldwide in businesses where high quality, superior performance, rugged reliability and long-term value are paramount. For more information, log on to www.oshkoshcorporation.com.
®, ™ All brand names referred to in this news release are trademarks of Oshkosh Corporation or its subsidiary companies.
Forward-Looking Statements
This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including, without limitation, statements regarding the Company’s future financial position, business strategy, targets, projected sales, costs, earnings, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations, are forward-looking statements. When used in this press release, words such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “should,” “project” or “plan” or the negative thereof or variations thereon or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, assumptions and other factors, some of which are beyond the Company’s control, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include risks related to the required increase in the rate of production for the M-ATV contract and the amount, if any, of additional orders for M-ATVs that the Company may receive; the cyclical nature of the Company’s access equipment, commercial and fire & emergency markets, especially during a global recession and credit crisis; the duration of the global recession, which could lead to additional impairment charges related to many of the Company’s intangible assets; the expected level and timing of U.S. Department of Defense procurement of products and services and funding thereof, including the outcome of the formal protests of the Family of Medium Tactical Vehicles (FMTV) award to the Company; risks related to reductions in government expenditures and the uncertainty of government contracts; the consequences of financial leverage associated with the JLG acquisition, which could limit the Company’s ability to pursue various opportunities; risks related to the collectability of receivables during a recession, particularly for those businesses with exposure to construction markets; risks related to production delays as a result of the economy’s impact on the Company’s suppliers; the potential for commodity costs to rise sharply, including in a future economic recovery; risks associated with international operations and sales, including foreign currency fluctuations; and the potential for increased costs relating to compliance with changes in laws and regulations. Additional information concerning these and other factors is contained in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this press release. The Company assumes no obligation, and disclaims any obligation, to update information contained in this press release.
Contact:
Oshkosh CorporationFinancial: Patrick DavidsonVice President, Investor Relations 920.966.5939 920.966.5939orMedia: Ann StawskiVice President, Marketing Communications 920.966.5959
Alcoa Recognized by Honda For Quality
Buzz up! 0 Print..Companies:Alcoa, Inc..
Business Wire - View Multimedia Gallery ...
Related Quotes
Symbol Price Change
AA 13.27 -0.27
{"s" : "aa","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Alcoa Inc. On Wednesday January 27, 2010, 11:16 am
NEW YORK--(BUSINESS WIRE)--Alcoa Latin America’s Utinga plant in Santo André, Brazil was recognized by Honda Motorcycle of Brazil for outstanding quality performance. Alcoa (NYSE:AA - News) received Honda’s top quality supplier award following Honda’s thorough assessment of its supplier network in Latin America over a 12-month period.
Alcoa is the exclusive supplier of extruded aluminum tubes for the rear suspension of several of Honda’s popular motorcycles, including the XRE300, CB250 Twister, and the CRF 30F and XR250 Tornado models for the Latin American market.
A motorcycle’s suspension serves a dual purpose, contributing to the vehicle’s handling and braking, and providing safety and comfort by keeping the vehicle’s passengers comfortably isolated from road noise, bumps and vibrations.
“We are always looking for solutions to improve performance and safety. By using Alcoa’s lighter, high-strength 7XXX series aluminum alloy in the suspension system, we improved the motorcycle’s performance significantly by reducing the weight of the swing arm, meeting our customer’s expectation,” said Luiz Antonio Azevedo Rosa, Quality Superintendent for Alcoa Extruded Parts Division, Brazil.
The Utinga plant supplies extrusions to a number of Latin American market segments, including the ground transportation, industrial machinery and electrical equipment markets, and consumer goods industries.
About Alcoa
Alcoa is the world leader in the production and management of primary aluminum, fabricated aluminum and alumina combined, through its active and growing participation in all major aspects of the industry. Alcoa serves the aerospace, automotive, packaging, building and construction, commercial transportation and industrial markets, bringing design, engineering, production and other capabilities of Alcoa's businesses to customers. In addition to aluminum products and components including flat-rolled products, hard alloy extrusions, and forgings, Alcoa also markets Alcoa® wheels, fastening systems, precision and investment castings, and building systems. The Company has been named one of the top most sustainable corporations in the world at the World Economic Forum in Davos, Switzerland and has been a member of the Dow Jones Sustainability Index for eight consecutive years. Alcoa employs approximately 59,000 people in 31 countries across the world. More information can be found at www.alcoa.com
Caption: Alcoa’s Utinga plant in Brazil received a quality supplier award from Honda Motorcycle of Brazil. Alcoa is the exclusive supplier of extruded aluminum tubes for the rear suspension of several Honda motorcycles, including the XRE300 pictured here.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6157472&lang=en
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6157472
Contact:
Alcoa Inc.Kevin G. Lowery, 412-553-1424 412-553-1424Kevin.lowery@alcoa.com
IMAI .18 x .20 8.5K vol up .01